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General Introduction
Candida albicans is a dimorphic yeast that often resides in the gastrointestinal and 
genital tract of the human host in a commensal interaction [1, 2]. However, in clinical 
situations in which the host defense decreases, C. albicans can become an opportunistic 
pathogen and can cause infections of the mucosa and, through blood dissemination, 
it can invade other organs. Mucosal Candida infections are mainly described at the 
level of the mouth, pharynx and esophagus (oropharyngeal candidiasis – OPC) or at 
the level of the vagina (vulvovaginal candidiasis – VVC). These infections are often 
seen in pregnant women, patients with diabetes or HIV, or those receiving immuno-
suppressive therapy or antibiotics, and they determine a significant decrease in the 
life quality, although they are very rarely fatal [3, 4]. In contrast, disseminated Candida 
infections are a major complication of neutropenia or immunosuppressive treatment, 
major surgery or lengthy Intensive Care Unit (ICU) stay [5-7]. The systemic Candida 
infections are characterized by a high mortality reaching 30 to 40% [8]. Although 
other Candida species can be related to disseminated candidiasis, the most common 
strain associated with human pathologies is Candida albicans [5, 6].
Although several risk factors for fungal infections have been previously described, as 
noted above, many patients develop mucosal infections such as recurrent VVC (RVVC) 
without any risk profile [9]. Moreover, only a small minority of patients at risk 
develops a systemic fungal infection [10]. These facts strongly argue that host factors 
such as the genetic make-up is likely to play a crucial role in determining which 
patients will develop Candida infections. This thesis will focus on the study of the 
genetic variation in host defense genes that may determine an increased susceptibility 
to infections caused by Candida spp. 
Host defense against Candida albicans is initiated by the recognition of the yeast by 
the innate immune system. Recognition is enabled by a large diversity of receptors 
known as pattern recognition receptors (PRRs), that detect conserved molecular 
structures of pathogens called pathogen-associated molecular patterns (PAMPs). 
Detection of PAMPs depends on different families of PRRs, such as Toll-like receptors 
(TLRs), C-type lectin receptors (CLRs), NOD-like receptors (NLRs), and RIG-I-like helicases, 
all acting in a coordinated manner to initiate downstream signaling in innate immune 
cells, thereby inducing production of proinflammatory cytokines and activation of 
T-cell responses [11].
Two classes of PRRs have been described to be the most important receptors for C. 
albicans recognition: Toll-like receptors (TLR) and lectin-like receptors (LR) [12]. TLR4 
and mannose receptor (MR) detect cell wall mannans [13], while TLR2/TLR1 and TLR2/
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TLR6 heterodimers detect phospholipomannans [14]. In addition, TLR2 acts in synergy 
with the archetypical β-glucan receptor dectin-1 for the production of proinflammatory 
cytokines [15-17]. Dectin-1 can also induce TLR-independent signals for the production 
of IL-17, IL-6 and IL-10 through a Syk/CARD9-dependent pathway [18]. The dectin-1 
receptor is expressed mainly by cells of the myeloid lineage (monocytes/macrophages, 
dendritic cells, and neutrophils) [19]. Moreover, the ability of the dectin-1 receptor to 
synergize with TLR2 and TLR4 promotes pro-inflammatory cytokine production and 
induction of Th1 and Th17 mediated host defense against C. albicans [15]. A scheme of 
Candida recognition by the PRRs can be found in Figure 1. 
Figure 1   Recognition of the Candida albicans cell wall components by the innate immune 
system. The Pattern recognition receptors (PRRs) are present in cells of the myeloid 
lineage (dendritic cells, neutrophils and monocytes/macrophages) and recognize 
conserved pathogen-associated molecular patterns (PAMPs). The signal is transduced  
by different pathways, activating NF-κB and the expression of pro-inflammatory 
cytokines.
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A large part of the genetic variation in the human genome is represented by single 
nucleotide polymorphisms (SNPs). Previously, a Dutch family was described with 
members suffering from onycomycosis and recurrent vulvovaginal candidiasis, in 
which genetic studies have demonstrated that the presence of an early stop 
polymorphism (Y238X rs16910526) in the DECTIN-1 gene led to a partial or total 
deficiency in β–glucan recognition. This defect led to an impaired recognition of C. 
albicans and decreased cytokine production by immune cells, especially for cytokines 
involved in the T-helper (Th) 17 pathway [20], and was also associated with a 3-fold 
higher susceptibility to mucosal colonization and infections in patients undergoing 
stem cells transplantation [21]. The support for the hypothesis of an important role of 
dectin-1 recognition for anti-Candida defense was provided by the description of 
another family with a defective CARD9 gene [22].
In Chapter 2, the effect of genetic variation in Dectin-1 and CARD9 on the prevalence 
of candidemia will be explored. The genotype of the rs16910526 Y238X SNP in DECTIN-1 
and the S12N rs4077515 SNP in CARD9 will be analyzed and compared with both 
functional and clinical data. 
Inflammation is an essential part of the immune response against infection, and 
cysteine protease enzymes of the caspase family have been shown to have a crucial 
role in inflammatory processes [23]. One important member of the caspase family is 
caspase-12. Caspase-12 is an inflammatory caspase, in which a loss-of-function genetic 
variant has been fixed in some populations by still undefined evolutionary pressures 
[24]. This loss-of-function is due to the presence of a T/C single nucleotide poly - 
morphism on nucleotide position 125 in the CASPASE-12 gene [25]. Although the 
ancestral variant is still present in African populations, of which 20–30% express the 
active variant of caspase-12, it is absent in Asian and Caucasian populations [25]. 
Functional studies have suggested that functional caspase-12 is a negative regulator 
of caspase-1 activation, which might result in lower cytokine production in response 
to recognition through PRRs. Thus, based on the proposed inhibitory effect on 
caspase-1 and, consequently, lower IL-1β and IL-18 production, functional caspase-12 
may have an effect on the immune homeostasis, which as a consequence can result 
in an increased susceptibility to severe sepsis and/or worsen the clinical outcome of 
sepsis patients [25]. In Chapter 3 the effect of the CASPASE-12 genotype on the 
susceptibility to Candida sepsis in African-American patients will be evaluated. 
Another important process for host defense is autophagy. Autophagy is an evolutionary 
conserved housekeeping molecular process important for cellular development, 
maintenance, energy turnover and antigen presentation. The autophagy machinery 
leads to the sequestration of components of the cytoplasm into double membrane 
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vesicles that ultimately fuse with the lysosome for degradation of the autophagosomal 
content [26]. Previous studies have demonstrated that genetic variation in autophagy 
genes affects the modulation of inflammation by autophagy [27]. Related to the 
autophagy process, a genetic variant in ATG16L1 (Thr300Ala, rs2241880) has been 
related with predisposition to Crohn’s disease, with the ATG16L1*300A conferring a 
higher risk [28-30]. Similarly, genetic polymorphisms in the IRGM (Immunity-related 
GTPase family M protein) gene are also associated with susceptibility to Crohn’s 
disease [31]. Interestingly, it has been shown that one of these IRGM SNPs, rs13361189 
SNP, is in perfect linkage disequilibrium with a 20 kb insertion/deletion polymorphism 
situated upstream of the IRGM promoter region. Consequently, this genetic variant 
modulates the expression of the IRGM gene [32].
Moreover, recent studies have shown that this ATG16L1 polymorphism not only influences 
autophagy [33], but also modulates proinflammatory cytokine responses, especially 
IL-1β [34], and thus interferes with the host defense against microorganisms such as 
mycobacteria [35]. We have therefore hypothesized that genetic variation in autophagy 
genes may influence inflammation and host defense during fungal infections, in 
particular candidemia. In Chapter 4, studies assessing the relation of the polymorphisms 
in ATG16L1 (rs2241880) and IRGM (rs13361189 and rs4958847) with predisposition to 
oropharyngeal candidiasis (OPC) and candidemia will be described.
Downstream signals transduced from the PRRs lead to the production of the inactive 
pro-cytokine form of IL-1β. Pro-IL-1β requires to be cleaved by the cysteine protease 
caspase-1 in order to be activated and secreted. In turn, activation of caspase-1 is 
under control of a protein complex called the inflammasome [39]. The inflammasome 
consists of a NLR protein [40], pro-caspase-1 and apoptosis-associated speck-like 
protein (ASC) [41]. After the interaction of the protein complex with a specific ligand, 
caspase-1 is activated and cleaves pro-IL-1β into the active form that is secreted from the 
cell through the pannexin-1 channel. A schematic representation of the inflammasome 
complex is shown in Figure 2. Th17-mediated immune responses against C. albicans, 
and thus antifungal mucosal host defense, relies strongly on IL-1β production [38].
In addition to systemic candidiasis and RVVC, oropharyngeal candidiasis  (OPC) is an 
opportunistic infection that characterizes HIV infection. In addition to OPC, other 
common opportunistic infections in HIV positive patients are Mycobacterium avium 
complex (MAC) disease, Pneumocystis carinii pneumonia (PCP), cytomegalovirus (CMV) 
retinitis, extrapulmonary cryptococcosis, toxoplasmic encephalitis, tuberculosis, chronic 
herpes simplex, disseminated histoplasmosis and chronic cryptosporidiosis [42]. 
However, not all HIV patients with low CD4+ counts will eventually develop opportunistic 
infections. We hypothesize that genetic variation in the Dectin-1/CARD9 pathway 
1GENERAL INTRODUCTION AND OUTLINE OF THE THESIS
15
may affect the predisposition to opportunistic infections in immunocompromised 
HIV positive patients. The effect of the genotype in DECTIN-1 and CARD9 on the 
susceptibility of OPC and other opportunistic infections in HIV positive patients will 
be assessed in Chapter 5. 
Not only susceptibility to systemic candidiasis may be influenced by genetic poly-
morphisms, but predisposition to mucosal fungal infections as well. In addition to 
the dectin-1 early stop codon, the mutant allele of the cytosine to thymine variation 
in the promoter region of the IL-4 gene (C589T) was related to a higher susceptibility 
to RVVC [36]. Moreover, a link between susceptibility to RVVC and the Gly54Asp SNP 
in the MBL gene, coding for Mannose binding lectin (MBL), was described. In this 
study it was demonstrated that the mutant allele was associated with reduced 
Figure 2   Caspase-1 maturation through the inflammasome complex. A first stimulus 
promotes the secretion of the inactive form of IL-1β and IL-18, while a second stimulus 
promotes the formation of the Caspase-1, NLRP3 and ASC inflammasome complex, 
leading the Caspase-1 activation and subsequent cleavage and activation of IL-1β and 
IL-18 by Caspase-1. Finally, the biologically active forms of IL-1β and IL-18 are secreted 
through the Pannexin-1/P2X7 channel.
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vaginal MBL concentrations [37]. Finally, the relation between the genotype for a 
variable number tandem repeat polymorphism (VNTR) in intron 4 of the gene coding 
for the NACHT-LRR-PYD-containing protein 3 (NLRP3) with the incidence of RVVC and 
vulvar vestibulitis syndrome (VVS) was demonstrated [38]. In Chapter 6 I will study 
the effect of genetic variation in genes related to PRRs in susceptibility to RVVC. 
The dectin-1 (Y238X, rs16910526), CARD9 (S12N, rs4077515), mannose receptor (rs1926736, 
Ser396Gly), TLR1 (rs5743611, Arg80Thr), TLR2 (rs5743704, Pro631His) and TLR4 (rs4986790, 
Asp299Gly, rs4986791, Thr399Ile) genetic variants will be assessed for their role in 
RVVC susceptibility. Furthermore, the functional effects of these genetic variants for 
cytokine production will be investigated.
In order to present an up-to-date overview of the knowledge regarding genetic 
susceptibility to RVVC, in Chapter 7 I will provide a bibliographic review concerning 
the relation between genetic variations and susceptibility to this important mucosal 
Candida infection. 
Finally, an overall summary of the findings presented in this thesis will be presented 
in Chapter 8. In this same chapter I will also propose future directions to follow for the 
increase in our understanding of the role of genetic variation in the host genome and 
Candida infections.
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Abstract
Background. Candidemia is an important cause of morbidity and mortality in critically 
ill patients or patients undergoing invasive treatments. Dectin-1 is the main β-glucan 
receptor, and patients with a complete deficiency of either dectin-1 or its adaptor 
molecule CARD9 display persistent mucosal infections with Candida albicans. The role 
of genetic variation of DECTIN-1 and CARD9 genes on the susceptibility to candidemia 
is unknown.
Methods. We assessed whether genetic variation in the genes encoding dectin-1 and 
CARD9 influence the susceptibility to candidemia and/or the clinical course of the 
infection in a large cohort of American and Dutch candidemia patients (n = 331) and 
noninfected matched controls (n = 351). Furthermore, functional studies have been 
performed to assess the effect of the DECTIN-1 and CARD9 genetic variants on 
cytokine production in vitro and in vivo in the infected patients.
Results. No significant association between the single-nucleotide polymorphisms 
DECTIN-1 Y238X and CARD9 S12N and the prevalence of candidemia was found, despite 
the association of the DECTIN-1 238X allele with impaired in vitro and in vivo cytokine 
production.
Conclusions. Whereas the dectin-1/CARD9 signaling pathway is nonredundant in 
mucosal immunity to C. albicans, a partial deficiency of β-glucan recognition has a 
minor impact on susceptibility to candidemia.
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Introduction
In developed countries, candidemia is one of the most prevalent bloodstream infections 
in hospital settings and is associated with significant morbidity and mortality. 
Candidemia is a systemic infection with Candida spp, predominantly Candida albicans, 
that occurs mostly in patients that are immunocompromised due to neutropenia, the 
use of broad-spectrum antibiotics, or invasive surgery, or by total parenteral nutrition 
[1, 2]. The first line of defense against fungal infections is the innate immune system 
that initiates recognition and initial elimination of pathogens, and subsequently 
induces the activation of adaptive immunity. Pattern recognition receptors (PRRs) are 
expressed by innate immune cells, and they specifically recognize moieties expressed 
on the surface of the microbial pathogens, designated as PAMPs (pathogen-associated 
molecular patterns) [3].
The recognition of PAMPs relies on several families of PRRs, such as Toll-like receptors 
(TLRs), C-type lectin receptors (CLRs), NOD-like receptors (NLRs), and RIG-I helicases, 
all acting in concert to activate downstream signaling in innate immune cells, thereby 
inducing production of proinflammatory cytokines and activation of T-cell responses 
[4]. In the case of fungal pathogens, it is especially TLRs and CLRs that mediate 
recognition [3]. Among the PRRs recognizing C. albicans, the archetypal CLR dectin-1 
detects β-glucans [5-8], which comprise 40% of the total cell wall of C. albicans. Upon 
β-glucan recognition, intracellular signaling is induced involving the adaptor proteins 
spleen tyrosine kinase (Syk) and CARD9 (caspase recruitment domain family member 
9), as well as Bcl-10 and Malt1, ultimately activating the transcription factor nuclear 
factor kappa-light-chain enhancer of activated B cells (NF-κB) [7, 9]. The dectin-1 
receptor is expressed mainly by cells of the myeloid lineage (monocytes/macrophages, 
dendritic cells, and neutrophils) [7, 10]. 
Previously, we described a Dutch family with members suffering from onycomycosis 
and recurrent vulvovaginal candidiasis, in which genetic studies have demonstrated 
that the presence of an early stop mutation in the DECTIN-1 gene led to a partial or 
total deficiency in β–glucan recognition [11]. This genetic defect resulted in impaired 
recognition of C. albicans and decreased cytokine production by immune cells, 
especially for cytokines involved in the T-helper (Th) 17 pathway [11]. The support for 
the hypothesis of an important role of dectin-1 recognition for mucosal anti-Candida 
defense was provided by the description of another family with a defective CARD9 
gene. Interestingly, family members with CARD9 deficiency exhibited a similar clinical 
phenotype with predominantly recurrent mucocutaneous Candida infections. Non- 
functional CARD9 was also associated with defects in Th17 responses [12]. Of note, 
patients with nonfunctional dectin-1 appeared not to be predisposed to invasive 
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Candida infection, whereas CARD9-deficient patients were severely prone to develop 
invasive Candida infections, especially in the brain [11, 12].
These studies implicate the dectin-1/CARD9 pathway as non-redundant in mucosal 
host defense against C. albicans. However, the role of the dectin-1/CARD9 innate 
pathway for the host defense against systemic Candida infections has not been 
directly investigated, although it would be expected to be less important. In the 
present study, a cohort of patients with candidemia has been studied for the potential 
association of susceptibility to candidemia with genetic variation in the DECTIN-1 and 
CARD9 genes. The early stop codon mutation in the DECTIN-1 gene that was previously 
characterized in the Dutch family described above is a polymorphism with a general 
allele frequency of 6%–8% in Caucasian populations and 4% in African populations. 
This polymorphism, which clearly affects dectin-1 function, could therefore be studied 
as a population-wide potential determinant in susceptibility to candidemia. In 
contrast, the mutation in the CARD9 gene causing CARD9 deficiency is a very rare 
mutation, which until now was only found in 1 family [12]. Alternatively, a common 
genetic variation in the coding region of the CARD9 gene has been detected with a 
single-nucleotide polymorphism (SNP) at amino acid position 12. This nonsynonymous 
SNP leads to an amino acid substitution from a serine to an asparagine residue. 
Because of its potential to influence CARD9 function and high minor allele frequency 
in both Caucasian (53%) and African (25%) populations, this SNP was also selected in 
this genetic study [13]. Therefore, the aim of this study was to determine whether 
these DECTIN-1 and CARD9 SNPs influence susceptibility to candidemia.
Materials and Methods
Patients
Patients were enrolled after informed consent (or waiver as approved by the institutional 
review board) at the Duke University Hospital (DUMC, Durham, North Carolina) and 
Radboud University Nijmegen Medical Center (RUNMC, Nijmegen, the Netherlands). 
The study was approved by the institutional review boards at each study center, and 
enrollment occurred between January 2003 and January 2009. The clinical characteristics 
of the patients, both infected and non-infected, are presented in Table 1.
To be included in the analysis of susceptibility to infection, infected subjects must 
have had at least 1 positive blood culture for a Candida species while hospitalized at 
the participating center. Non-infected controls must have been hospitalized with no 
history or evidence of candidemia/invasive candidiasis or any invasive fungal infection. 
Non-infected controls were recruited from the same hospital wards as infected patients 
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so that comorbidities and clinical risk factors for infection would be similar between 
groups. Intergroup comparisons between the 2 groups of non-infected subjects and 
between the 2 groups of infected subjects (at DUMC and RUNMC) were performed 
regarding similarity in genetic distribution of the studied SNPs prior to further statistical 
Table 1   Baseline Patient Characteristics for DUMC Infected Cohort (n = 291) and Control 
Cohort (n = 300). Including Caucasian and African-American Adult Patients
Variable Infected cohort Control cohort
Mean age (years) 55.9 57.8
Immunocompromised State 59% 38%
HSCT 1% 0%
Solid organ transplant 12% 2%
Active Malignancy*  
Solid Tumor
Leukemia
Lymphoma
32%
23%
7%
4%
20%
12%
5%
4%
Chemotherapy within past 3 months 17% 11%
Neutropenia (ANC <500 cells/mm3) 10% 4%
HIV-infected 2% 0.1%
Surgery within past 30 days 43% 48%
Receipt of Total Parenteral Nutrition 19% 4%
Dialysis dependent 12% 7%
Acute Renal Failure 34% 22%
Liver Failure 25% 4%
Intensive Care Unit Admission within past 
14 days
49% 34%
Bacteremia within past 48 hours 24% 2%
Median Baseline Serum Creatinine (mg/dL) 1.3 1.0
Median Baseline WBC count (cells/mm3) 10.55 8.55
Candida spp. **
albicans
glabrata
parapsilosis
tropicalis
krusei
other Candida spp.
42%
29%
16%
13%
4%
3%
-
NOTE. ANC, absolute neutrophil count; DUMC, Duke University Hospital; HIV, human immunodeficiency 
virus; HSCT, hematopoietic stem cell trans- plantation; WBC, white blood cell.
1 a Subjects could have .1 species isolated. 
2 b Sixteen subjects had .1 species isolated.
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analysis of infected versus non-infected subjects. Subjects were excluded from the study 
if insufficient volume of blood or clinical data were available to allow for analysis.
Genetic Analysis
Genomic DNA was isolated from whole blood using standard procedures. Genotyping 
for the DECTIN-1 Y238X (c.714T > G, rs16910526) and CARD9 S12N (c.35G > A, rs4077515) 
polymorphisms was performed by using the TaqMan single nucleotide assay 
C_33748481_10 and C_25956930_20, respectively, on the 7300 ABI real-time poly- 
merase chain reaction system (all from Applied Biosystems).
Genetic Association With Clinical Outcomes
Due to the lack of detailed clinical data on the Dutch candidemia patients (n = 40) and 
controls (n = 51) recruited at RUNMC, the correlations of the genetic data with clinical 
outcome were performed with the North American patients (n = 291) and controls (n 
= 300) from DUMC only. Infected subjects at DUMC were followed prospectively for 
up to 12 weeks following diagnosis of candidemia to determine clinical outcome: [1] 
disseminated disease, [2] persistent fungemia, and [3] all-cause mortality at 30 days. 
Disseminated infection was defined as the presence of Candida spp. at normally 
sterile body sites outside the bloodstream (excluding the urine). Persistent fungemia 
was defined as ≥5 days of persistently positive blood cultures. This analysis was 
performed in the entire infected cohort, as the progression of the disease once 
occurring is not expected to differ between European and African-American patients, 
and race was considered a covariate in the analysis. Variables with P value <.2 were 
further assessed in a multivariable logistic regression model. Variables with P < .05 
were retained in the final predictive model. Odds ratios and 95% confidence intervals 
were reported for variables that remained significant in the final multivariable model. 
Cytokine Stimulation Assays 
PBMCs were isolated from healthy volunteers by Ficoll-Paque gradient. Subsequently, 
stimulation with heat-killed C. albicans was performed for 24 hours, 48 hours, or 7 
days. The stimulation time varied for each cytokine, being 24 hours for tumor necrosis 
factor (TNF)–α, interleukin (IL)–1β, IL-6, and IL-8, 48 hours for interferon (IFN)–γ, and 
7 days for IL-17 production. For the 7-day culture, the medium was supplemented with 
10% human serum. After the incubation time, the above-mentioned cytokines were 
measured in the supernatants by enzyme-linked immunosorbent assay (purchased 
from R&D Systems or Sanquin Research).
Serum Cytokine Measurements
Cytokine concentrations of IL-6, IL-8, and IFN-γ in plasma and serum samples obtained 
from infected patients from day 1 up to day 5 after initial positive blood culture were 
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measured by multiplex fluorescent bead immunoassay (xMAP technology, Bio-Rad) 
and a BioPlex microbead analyzer (Luminex) according to the manufacturer’s protocol.
Bioinformatic Analysis
In order to predict the effect on the conformation of the CARD9 protein given the 
S12N amino acid change, we used HOPE (http://www.cmbi.ru.nl/hope/), a web server 
that performs automatic mutant analysis. No homology model was produced 
because no template with enough identity to the CARD9 sequence exists [14]. We 
also used the Polyphen software in order to determine quantitatively the damage for 
the protein stability taking into account the amino acid change of the CARD9 SNP [15]. 
Statistical Analysis
For the analysis of SNPs, statistical comparisons of frequencies were made between 
infected versus non-infected subjects and of clinical parameters within the infected 
group using the χ2 test with SPSS version 16.0 software. Data were analyzed for 
Caucasian descendants separately from African-Americans, as allelic frequencies 
were expected to differ between these 2 populations. For the analysis of the in vitro 
PBMC stimulation and in vivo serum cytokine measurements, a Mann–Whitney U 
test was performed on the DECTIN-1 genotype experiment and a Kruskal–Wallis -1way 
analysis of variance was performed on the CARD9 genotype experiment with the use 
of GraphPad Prism software version 4.00.
Results
Genetic Analysis
Data from adult patients (n = 331 (291 North American and 40 Dutch)) and controls 
(n = 351 (300 North American, 51 Dutch]) were included in the analysis for genetic 
association with susceptibility to infection. Data from children were excluded from 
this analysis because the number of children enrolled (n = 27) was insufficient to 
analyze this association extensively in a pediatric population, where factors relating 
to susceptibility to candidemia may differ from those for adults.
The intergroup comparison between the Dutch RUNMC and North American 
Caucasian DUMC non-infected controls and between the infected subjects recruited 
at DUMC and RUNMC revealed a similar genetic distribution of the genotyped SNPs, 
which allowed the groups to be merged into 1 group of non-infected controls and 1 
group of infected subjects (data not shown). In contrast, the African-American 
patients from the DUMC cohort displayed a different genetic pattern, and they were 
analyzed separately. Genetic distribution of the DECTIN-1 Y238X and CARD9 S12N 
CHAPTER 2
28
polymorphisms in the studied patient groups is shown in Tables 2 and 3, respectively. 
The genotyping of candidemia patients and non-infected matched controls for 
polymorphisms in DECTIN-1 and CARD9 revealed no significant association with 
susceptibility to candidemia. After statistical analysis of the Dutch and the North 
American cohorts separately, again no significant differences were obtained (data 
not shown). Similarly, no differences were observed when data were analyzed 
separately in non-neutropenic and neutropenic patients (data not shown). A post hoc 
analysis of power for the dectin-1 polymorphism demonstrated that we had 86.7% 
power to detect a 10% difference in frequency in the Caucasian cohort, with 238 
infected and 263 non infected subjects, with a 2-sided a α = .05. For African-Americans, 
a post hoc analysis of power for dectin-1 polymorphism demonstrated that we had 
76% power to detect a 10% difference in frequency, with 93 infected and 88 
non-infected subjects, also with a 2-sided a α = .05.
In order to study the role of these genetic variants in the clinical outcome of 
candidemia, clinical parameters on dissemination, persistence, and 30-day mortality 
of infected patients were correlated with the DECTIN-1 and CARD9 genotype. Because 
these data were only available for the North American cohort, for these analyses the 
Table 2   Frequencies of the genotype of the DECTIN-1 early stop polymorphism Y238X and the 
incidence of candidemia in African American and Caucasian patients
TT (%) TG (%) GG (%) P-valuea
African-American Non-Infected (N = 88) 95.5 4.5 0 0.515
Infected (N=93) 97.1 2.9 0
Caucasian Non-Infected (N=263) 83.4 16.6 0 0.624
Infected (N=238) 83.9 15.7 0.4
a P values were calculated with the χ2 test.
Table 3   Frequencies of the genotype of the CARD9 Ser12Asn polymorphism and the 
incidence of candidemia in African American and Caucasian patients
GG (%) GA (%) AA (%) P-valuea
African-American Non-Infected (N=88) 44.2 50.7 5.2 0.305
Infected (N=93) 49.5 40.8 9.7
Caucasian Non-Infected (N=263) 34.1 48.3 17.6 0.413
Infected (N=238) 40.3 43.0 16.7
a P values were calculated with the χ2 test.
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Dutch patients were excluded. No significant associations between DECTIN-1 and 
CARD9 polymorphisms and clinical parameters were observed in these analyses 
(Table 4). Minor differences in the clinical characteristics of the control and candidemia 
groups have been observed. Although we cannot completely rule out that these 
differences might have caused the lack of effect of the polymorphisms, from the 
clinical point of view these differences were not as big as to expect major effects.
Functional Analysis of Cytokine Profiles
In order to assess the functional consequences of the SNPs in DECTIN-1 and CARD9, 
both in vitro and in vivo cytokine measurements were performed. The in vitro evaluation 
was performed by measuring cytokine production upon heat-killed Candida stimulation 
of PBMCs with different DECTIN-1 and CARD9 genotypes, obtained from healthy 
volunteers. The results of these in vitro assays are shown in Figure 1. Significant 
differences in cytokine production were observed between cells obtained from 
individuals with different DECTIN-1 genotypes, including decreased production of 
TNF-α (P = .003) and IL-1β (P < .0001), while differences in the production of IL-6, IL-8, 
IFN-γ (Figure 1), and IL-17 (data not shown) were not statistically significant. In 
contrast, no effect of the CARD9 polymorphism on C. albicans–induced cytokine 
production was apparent.
Table 4   Univariate Analysis of the Association Between the DECTIN-1 and CARD9 
Polymorphisms With Disseminated Disease, Persistent Fungemia, and 30-day 
Mortality in the DUMC Infected Cohort (n = 291).
Genotype DECTIN-1 Y238X CARD9 S12N
No disseminated disease (n = 268) 11.6% 56.9%
Disseminated disease (n = 63) 15.0% 61.5%
P valuea .46 .54
No persistent fungemia (n = 280) 12.1% 56.6%
Persistent fungemia (n = 51) 12.8% 64.3%
P valuea .90 .35
Survivors (n = 238) 13.4% 56.8%
Non-survivors (n = 93) 9.0% 60.0%
P valuea .29 .61
NOTE. Numbers are the percentages of patients with each outcome who were found to bear the mutant 
allele of the particular polymorphism.
a P values were calculated with the χ2 test.
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Figure 1   Functional analysis on the stimulation of the peripheral blood mononuclear cells 
(PBMCs) with heat-killed Candida albicans blastoconidia. Cytokine production 
capacity of tumor necrosis factor alpha (TNFα), interleukin (IL)–1β, IL-6, IL-8, and 
interferon (IFN)-γ was compared between the cells obtained from healthy volunteers 
bearing wild-type or variant DECTIN-1 or CARD9 single-nucleotide polymorphisms 
(SNPs). He, heterozygous; Ho, homozygous; Wt, wild type. Data are presented  
as mean ± SEM. *P < .05 (Mann–Whitney U test or Kruskal–Wallis 1-way analysis of 
variance).
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Serum samples collected from infected patients during the first 5 days after initial 
positive blood culture were measured for concentrations of IL-6, IL-8, and IFN-γ (Figure 2). 
In general, the IL-6, IL-8, and IFN-γ production decreased over time. Correlation with 
the genotype of the patients revealed that patients heterozygous for the DECTIN-1 
polymorphism had lower cytokine concentrations at the initiation of infection, which 
remained low throughout the follow-up period. No differences in cytokine-circulating 
concentrations were apparent between individuals bearing different CARD9 genotypes.
Figure 1   Continued.
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Discussion
In the present study, we assessed the influence of genetic polymorphisms in the genes 
encoding dectin-1 and CARD9 for susceptibility to candidemia. Patients heterozygous 
for the DECTIN-1 Y238X polymorphism exhibited moderately lower cytokine responses 
compared with individuals bearing wild-type DECTIN-1 genotypes, whereas no effects 
Figure 2   Cytokine concentrations of interleukin (IL)–6, IL-8, and interferon (IFN)-γ in plasma 
and serum samples obtained from infected patients from day 1 up to day 5 after 
initial positive blood culture correlated with the DECTIN-1 or CARD9 genotype. HET, 
heterozygous. HOM, homozygous; WT, wild type. Data are presented as mean ± 
SEM. *P < .05 (Mann–Whitney U test or Kruskal–Wallis 1-way analysis of variance).
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of the CARD9 SNP on these responses were observed. Despite these differences, the 
genetic variation in DECTIN-1 and CARD9 was not associated with susceptibility to 
candidemia.
Polymorphisms in several PRRs have been suggested to be associated with a higher 
risk to fungal infections [16-19]. Recent studies have unveiled genetic variants of 
DECTIN-1 and CARD9 that predispose to mucocutaneous fungal infections [11, 12]. 
Individuals heterozygous for the DECTIN-1 Y238X allele have also been shown to 
display increased colonization with Candida when they suffer from hematological 
malignancies, leading to more frequent prescription of prophylactic antifungal 
therapy [20]. However, the role of genetic variability in these genes in susceptibility 
to candidemia was not known. Therefore, we have investigated whether SNPs in 
DECTIN-1 and CARD9 are associated with susceptibility to systemic Candida infection.
Dectin-1 is the most important receptor of β–glucans, and it plays an important role 
for induction of cytokines in human monocytes and macrophages [21, 22]. The 
DECTIN-1 Y238X polymorphism, the best characterized of the 2 SNPs analyzed in this 
study, clearly affects dectin-1 function [11], as confirmed by the in vitro cytokine data 
provided here. However, our data indicate that if patients are heterozygous for this 
DECTIN-1 polymorphism, neither susceptibility to Candida bloodstream infections, 
nor clinical parameters such as severity and dissemination of the infection or 30-day 
mortality, are affected. This might be due to the specific involvement of dectin-1 
recognition pathway in mucosal immunity to C. albicans, reflected by the induction of 
cytokines that are crucial for Th17 responses, including IL-6 and IL-17. In contrast, for an 
effective immune response to prevent Candida bloodstream infections, proinflam-
matory cytokines such as TNF-a, or Th1 responses releasing IL-18 and IFN-γ, may play a 
more important role. Indeed, the production of proinflammatory cytokines after 
stimulation of cells in vitro with C. albicans was only moderately decreased in 
individuals heterozygous for the DECTIN-1 Y238X SNP, and these data are supported 
by cytokine stimulation experiments from individuals with complete dectin-1 
deficiency [11], Unexpectedly, serum cytokine measurements of IFN-γ were found to 
be lower in patients heterozygous for the DECTIN-1 Y238X polymorphism, although 
this genetic variant does not seem to confer an additional risk to develop or worsen 
the outcome of candidemia. Presumably, the relatively high residual circulating 
cytokine concentrations in individuals bearing the DECTIN-1 polymorphism were 
sufficient to afford protection against candidemia. It can be therefore concluded that 
other PRRs and mechanisms of antifungal host defense can compensate for the 
deficit of dectin-1 function, especially at the tissue level where Candida invasion takes 
place.
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Several explanations are possible for why no association of the CARD9 S12N SNP with 
susceptibility to candidemia was observed. Because the consequences of the presence 
of the CARD9 polymorphism for its function have not been studied, one possibility is 
that this polymorphism only minimally affects the protein structure. A bioinformatic 
approach may assess the putative effect on the function of the molecule of the amino 
acid change from serine to asparagine in CARD9. Since in the Protein Data Bank there 
is no 3-dimensional model of the CARD9 protein available, as well as no modeling 
template to build a homology model, the analysis was made by comparing the amino 
acid composition of the protein bearing the mutation with the wild-type protein with 
the Swift Yasara twinset via the HOPE server [14]. This analysis generated evidence 
that the amino acid change is important because the mutation is located on position 
12 in the CARD domain. These domains occur in a wide range of proteins and are 
thought to mediate the formation of larger protein complexes via direct interactions 
between individual CARDs. Moreover, as serine and asparagine differ in size and 
hydrophobicity and the mutated residue is buried in the core of the protein, this 
change may also modify CARD9 function. Nevertheless, the Swift algorithm predicted 
that the polymorphism S12N is ‘‘allowed’’ [23], and the Polyphen algorithm predicts 
the effect of the serine to asparagine amino acid change as ‘‘benign’’ for protein 
function, taking into account that this residue position is not conserved through 
evolution [15], and this is supported by the lack of differences in cytokine production.
In conclusion, we demonstrate that genetic variations in SNPs of the dectin-1/CARD9 
pathway have no major impact on the susceptibility to systemic infections with C. 
albicans. The dectin-1/CARD9 recognition pathway seems therefore to be of high 
importance for mucosal antifungal host defense, whereas systemic immunity to 
Candida largely relies on alternative immune recognition pathways.
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The impact of caspase-12  
on susceptibility to candidemia
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Abstract
Candida is one of the leading causes of sepsis, and an effective host immune response 
to Candida critically depends on the cytokines IL-1β and IL-18, which need caspase-1 
cleavage to become bioactive. Caspase-12 has been suggested to inhibit caspase-1 
activation and has been implicated as a susceptibility factor for bacterial sepsis. 
In populations of African descent, CASPASE-12 is either functional or non-functional. 
Here, we have assessed the frequencies of both CASPASE-12 alleles in an African- 
American Candida sepsis patients cohort compared to uninfected patients with 
similar predisposing factors. African-American Candida sepsis patients (n = 93) and 
non-infected African-American patients (n = 88) were genotyped for the CASPASE-12 
genotype. Serum cytokine concentrations of IL-6, IL-8, and IFNγ were measured in the 
serum of infected patients. Statistical comparisons were performed in order to assess 
the effect of the CASPASE-12 genotype on susceptibility to candidemia and on serum 
cytokine concentrations. Our findings demonstrate that CASPASE-12 does not influence 
the susceptibility to Candida sepsis, nor has any effect on the serum cytokine 
concentrations in Candida sepsis patients during the course of infection. Although the 
functional CASPASE-12 allele has been suggested to increase susceptibility to bacterial 
sepsis, this could not be confirmed in our larger cohort of fungal sepsis patients.
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Introduction
One of the leading pathogens causing sepsis in immunocompromised hosts are 
Candida spp. [1, 2]. Medical conditions that lead to an immunocompromised state 
increase susceptibility to Candida sepsis [3]. In addition to exogenous factors, it is 
believed that genetic variation also plays an important role in susceptibility to sepsis 
[4-6]. Caspase-12 is an inflammatory caspase, in which a loss-of-function genetic 
variant has been fixed in some populations by still undefined evolutionary pressures 
[7-9]. This loss-of-function is due to the presence of a T/C single nucleotide poly- 
morphism (rs497116) on nucleotide position 125 in the CASPASE-12 gene [10]. Although 
the ancestral variant is still present in African and African-American populations, of 
which 20–30% express the active variant of caspase-12, it is absent in Asian and 
Caucasian populations [9, 10].
Functional studies have suggested that functional caspase-12 is a negative regulator of 
caspase-1 activation, which might result in less cytokine production in response to 
recognition through pattern recognition receptors. Thus, based on the proposed inhibitory 
effect on caspase-1 and, consequently, lower IL-1β and IL-18 production, functional 
caspase-12 may increase the susceptibility to severe sepsis and/or the clinical outcome 
of sepsis patients [10]. Therefore, it is compelling to assess whether genetic variation 
in CASPASE-12 plays a role in the susceptibility to Candida sepsis. The aim of this study 
was to assess whether genetic variants of CASPASE-12 influence the incidence, severity, 
and mortality of Candida sepsis in a cohort of African-American patients.
Materials and Methods
Subjects were enrolled between January 2003 and January 2009 after informed 
consent (or waiver, as approved by the Institutional Review Board) at the Duke 
University Hospital (DUMC, Durham, NC, USA). Infected subjects had ≥1 positive 
blood cultures for a Candida species while hospitalized. Non-infected controls were 
recruited from the same hospital wards as infected patients, with no history or 
evidence of Candida sepsis/invasive candidiasis or any invasive fungal infection.
Genomic DNA was isolated from whole blood using standard procedures. The region 
of interest of the CASPASE-12 gene was amplified as described previously [10].
Circulating cytokine concentrations of IL-6, IL-8, and IFNγ in infected patients were 
measured by Multiplex Fluorescent Bead Immunoassays (xMAP technology, Bio-Rad, 
Veenendaal, the Netherlands), from day 0 up to day 5 after the initial positive blood culture.
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Statistical comparisons of frequencies were made between infected versus non- 
infected subjects using Chi-square tests. Statistical analysis of the cytokine data was 
performed by using the Mann–Whitney U-test. Overall, a p-value < 0.05 was considered 
to be statistically significant.
Results
A total of 93 African-American patients and 88 non-infected African-American controls 
had genetic and clinical data available for the analysis. The demographic data for the 
study subjects are presented in Table 1.
No significant differences in the distribution of CASPASE-12 genotypes were seen 
when comparing infected patients (CC 3.9%, CT 25.3%, TT 72.4%) and non-infected 
controls (CC 2.9%, CT 30.0%, TT 66.1%) (p > 0.05). No associations between the 
CASPASE-12 genotypes and disseminated disease, persistent fungemia, or 30-day 
mortality were observed (data not shown).
Serum samples collected from infected patients during the first 5 days after the initial 
positive blood culture were measured for concentrations of IL-6, IL-8, and IFNγ. Also, 
measurements of IL-1β and IL-18 were performed in these samples. However, the 
concentrations of these cytokines were too low to detect (data not shown). Cytokine 
concentrations decreased over time. No differences in cytokine concentrations were 
apparent between individuals bearing different CASPASE-12 genotypes (Fig. 1). 
Caspase-12 has been suggested to inhibit caspase-1 processing of pro IL-1β and pro 
IL-18 into the active cytokines. Genetic variation of CASPASE-12 in populations of 
African descent has been previously associated with susceptibility to bacterial sepsis 
[10]. The present study was performed in order to assess the role of caspase-12 in 
sepsis caused by Candida spp. The results indicate that the CASPASE-12 genotype has 
no significant effect on the susceptibility and severity of systemic infections with 
Candida.
Candida is one of the leading pathogens causing sepsis [2, 11, 12]. Pro-inflammatory 
cytokines such as IL-1β and IL-18 are a crucial factor in eliciting an effective immune 
response to eradicate the infection. A modulatory step in the production of these 
cytokines is exerted at the level of caspase-1, a protease that cleaves the pro-form of 
these cytokines into shorter bioactive proteins [13, 14]. It has previously been reported 
that CASPASE-12 knockout mice were better capable of clearing both local and 
systemic bacterial infections compared to wild-type mice, through an improved 
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Table 1   Baseline patient characteristics of African-American patients with Candida systemic 
infection or uninfected controls recruited at the Duke University Hospital (DUMC, 
Durham, NC, USA) (n = 181).
Variable Infected cohort 
(n = 93), %
Control cohort 
(n = 88), %
Mean age (years) 52 52
Gender
Male 51.6 48.9
Female 48.4 51.1
Immunocompromised state 54.8 48.9
HSCT 0 0
Solid organ transplant 7.5 3.5
Active malignancy* 22.6 13.8
 Solid tumor 14 8.0
 Leukemia 5.4 3.5
 Lymphoma 3.2 2.3
Chemotherapy within past 3 months 12.9 5.6
Neutropenia (ANC <500 cells/mm3) 4.3 1.2
HIV-infected 5.4 0
Surgery within past 30 days 34.4 30.7
Receipt of total parenteral nutrition 19.4 5.75
Dialysis-dependent 15.1 8.0
Acute renal failure 36.6 33.0
Liver failure 25.8 1.2
Intensive care unit admission within the 
past 14 days
39.8 31.8
Median baseline serum creatinine (mg/dL) 2.27 1.9
Median baseline WBC count (cells/mm3) 13.0 10.87
Candida spp.**
 albicans 44.2 -
 glabrata 23.7 -
 parapsilosis 17.2 -
 tropicalis 10.8 -
 krusei 3.2 -
 Other Candida spp. 0.9 -
*Subjects could have more than one active malignancy
**Sixteen subjects had >1 species isolated
CHAPTER 3
42
inflammatory response [15]. The same authors described a similar effect of caspase-12 
in patients with bacterial sepsis, with individuals bearing functional caspase-12 being 
more susceptible to this condition [10]. However, the role of CASPASE-12 genetic 
variants in fungal sepsis has not been addressed so far.
Firstly, the comparison of CASPASE-12 genotype frequencies in African-American 
patients with non-infected controls revealed no statistically significant differences. 
Secondly, no effects of the CASPASE-12 genotype was observed in relation to the clinical 
outcome of infection, assessed as disseminated disease, persistent fungemia, and 
Figure 1   IL-6, IL-8, and IFNγ circulating concentrations in infected patients from day 0 up to 
day 5 after initial positive blood culture, in relation to the CASPASE-12 genotype. TC 
heterozygous, TT homozygous mutant. The data are presented as mean ± standard 
error of the mean (SEM).
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30-day mortality. Furthermore, serum cytokine concentrations during the first 5 days 
of infection were shown to be unaffected by the CASPASE-12 genotype.
Our findings on the lack of influence of the CASPASE-12 genotype on fungal sepsis 
contrast with those of Saleh et al. [10, 15] who suggested an important role of this 
genetic variant in bacterial sepsis. Moreover, circulating cytokine concentrations in 
infected patients were also not influenced by the CASPASE-12 genotype. It should be 
emphasized that this is, in particular, true for IL-6 and IFNγ, cytokines that are induced 
by IL-1β and IL-18, respectively [16-18]. This provides indirect evidence that functional 
caspase-12 has no clear effect on the production of IL-1β and IL-18 in the context of 
Candida sepsis. One possible explanation for the discrepancy between this study and 
that of Saleh et al. [10] is represented by the different cause of sepsis in the two 
studies, fungal and bacterial, respectively. However, one has to concede that the 
pro-inflammatory cytokines, of which production is reportedly regulated by 
the CASPASE-12 genotype, exert similar protective effects in bacterial and fungal 
sepsis [18-21]. In this respect, a recent study has also failed to reproduce the inhibitory 
effects of the CASPASE-12 genotype of lipopolysaccharide and Gram-negative bacte-
ria-induced cytokine production [22], bringing into question the biological activity of 
caspase-12.
In conclusion, although an effect of the CASPASE-12 genotype on the susceptibility to 
bacterial sepsis has been previously reported in a small cohort of African-American 
patients [10], this could not be confirmed in our larger cohort of fungal sepsis patients. 
Furthermore, clinical outcome and in vivo cytokine responses were not influence by 
the CASPASE-12 genotype. Therefore, we propose that caspase-12 is redundant for systemic 
host defense in sepsis.
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Abstract
Candida albicans can cause candidemia in neutropenic and critically ill patients, and 
oropharyngeal candidiasis in HIV-positive patients with low CD4+ counts. However, 
not all patients at risk develop Candida infections, and the genetic background of the 
patient might play a role in the susceptibility to infection. Autophagy mediates 
pathogen clearance and modulation of inflammation. The aim of this study was to 
assess the effect of genetic variation in the ATG16L1 and IRGM autophagy genes on 
the susceptibility to candidemia and oropharyngeal candidiasis.
We assessed whether genetic variation in the ATG16L1 and IRGM genes influences 
susceptibility to candidemia in a cohort of candidemia patients of both African and 
European origin. In addition, we assessed the effect of these polymorphisms for the 
susceptibility to oropharyngeal candidiasis in an HIV-positive cohort from Tanzania. 
Functional studies have been performed to assess the effect of the ATG16L1 and IRGM 
genetic variants on cytokine production both in vitro and in vivo. The results indicate 
that ATG16L1 variants modulate production of TNFα, but not other cytokines, while no 
effects were seen in the presence of IRGM polymorphisms. In addition, no significant 
associations between the SNPs in the ATG16L1 and IRGM genetic variants and the 
incidence of candidemia or oropharyngeal candidiasis were identified.
In conclusion, despite moderate effects on the modulation of proinflammatory 
cytokine production, genetic variation in the autophagy genes ATG16L1 and IRGM has 
a minor impact on the susceptibility to both mucosal and systemic Candida infections.
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Introduction
Candida albicans is a dimorphic fungus that is commensal in immunocompetent 
individuals, colonizing the skin, gastrointestinal tract and oral and genital mucosa. 
However, under certain host immune defense conditions, C. albicans can become 
pathogenic, being the most common fungal pathogen in humans [1]. C. albicans can 
cause both mucosal and disseminated infections. Candidemia is a systemic infection 
with Candida spp., predominantly but not limited to C. albicans, that occurs mostly in 
patients that are immunocompromised due to neutropenia, in critically-ill patients 
with use of broad spectrum antibiotics, invasive surgery, or in patients receiving total 
parenteral nutrition [2, 3]. Moreover, other risk factors such as ethnic background 
might also play a role based on the genetic differences between individuals of 
European vs. African ancestry [4]. Oropharyngeal candidiasis (OPC) is a Candida 
mucosal infection that occurs very often as an opportunistic infection in HIV positive 
patients with a low CD4+ count (<200 cells/µL) [5-7]. In the absence of proper 
treatment, the chance of spread of the infection to the bloodstream increases [8].
However, not all patients at risk develop Candida infections, and part of the differential 
susceptibility may be explained by the genetic makeup of the patients, as exemplified 
by several reports published previously [9-12]. Autophagy is a highly conserved 
housekeeping molecular process important for cellular development, maintenance, 
energy turnover and antigen presentation. The autophagy machinery enables the 
formation of double membrane vesicles leading to the sequestration of components 
of the cytoplasm into double membrane vesicles that ultimately fuse with the 
lysosome for degradation of the autophagosomal content [13]. Furthermore, 
autophagy is enabling the lysosomal digestion and antigen presentation of 
phagocytosed materials such as fungal and bacterial pathogens, including Candida 
spp. [14].
Previous studies have demonstrated that genetic variation in autophagy genes affect 
the modulation of inflammation by autophagy [15]. A genetic variant in ATG16L1 
(Thr300Ala, rs2241880) has been associated with susceptibility to Crohn’s disease, 
with the ATG16L1*300A conferring a higher risk [16-18]. Moreover, recent studies have 
shown that this ATG16L1 polymorphism not only affects the capacity to execute 
autophagy [19], but also to modulate proinflammatory cytokine responses, especially IL-1β 
[20], and influences host defense against microorganisms such as mycobacteria [21].
Similarly, genetic polymorphisms in the IRGM (Immunity-related GTPase family M 
protein) gene are associated with Crohn’s disease, including the SNPs rs13361189 and 
rs4958847 [22]. Interestingly, it has been shown that one of these IRGM SNPs, rs13361189, 
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is in perfect linkage disequilibrium with a 20 kb insertion/deletion polymorphism 
situated upstream of the IRGM promoter region. Consequently, this genetic variant 
modulates the expression of the IRGM gene [23].
Considering the data linking ATG16L1 and IRGM SNPs with the modulation of immune 
responses by autophagy, it is compelling to assess whether these genetic variants 
could influence the susceptibility to fungal infections, and in particular oropharyngeal 
and/or disseminated candidiasis because of their functional effects on the autophagy 
machinery. Although in a recent study we were not able to identify a crucial role of 
autophagy in systemic Candida infections [24], no information is available on the role 
of autophagy in mucosal infection with Candida. Interestingly, Candida albicans is 
also one of the immunogens for developing anti-Saccharomyces cerevisiae antibodies 
(ASCA), which are regularly observed in patients with mucosal lesions in Crohn’s 
disease [25, 26].
In order to determine the role of the genetic polymorphisms in two autophagy genes in 
the susceptibility to both systemic and mucosal infections with Candida albicans, we 
evaluated the frequency of the genotypes of three polymorphisms in the ATG16L1 and 
IRGM genes in the predisposition to two different types of Candida albicans infections: 
oropharyngeal candidiasis in HIV positive patients and disseminated candidiasis or 
candidemia in intensive care unit patients. In order to support the genetic analysis, 
functional assays were performed with peripheral blood mononuclear cells bearing 
different ATG16L1 and IRGM genotypes and serum cytokine measurements were 
conducted by comparing the genotypes for their ability to produce cytokines upon 
Candida albicans stimulation either in vitro or in vivo. Finally, a bioinformatic analysis 
was performed with the aim to further explain the possible functional consequences 
of the genetic variants in ATG16L1 and IRGM.
Patients and Methods
HIV positive patients
The effect of the polymorphisms associated with the autophagy process in the 
predisposition to OPC was assessed in a group of 155 HIV-seropositive patients recruited 
at the Muhimbili National Hospital HIV-clinic in Dar-es-Salaam, Tanzania. The 
recruitment period took place between April 2007 and August 2008. The patients’ 
clinical examination was performed by an independent physician according to the 
WHO clinical staging criteria [27]. The oral examination was routinely performed at 
each visit according to WHO rules [28]. Variations in color, size and shape of anatomical 
areas of the intraoral tissue were taken as clinical sings for OPC. The clinical manifestations 
of OPC in these patients were diverse, presenting a pseudomembranous candidiasis 
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or a combination of pseudomembranous and erythematous, hyperplastic, or angular 
cheilitis. This cohort has been previously reported in genetic association studies by 
our group [29], and the study was approved by the Ethical Committee of the Hospital. 
Sampling was performed by firmly swabbing the lesion site with a sterile cotton wool 
swab. Immediate microbiological confirmation was performed, the samples were 
sent immersed in 10% potassium hydroxide (KOH). Within this cohort, 82 patients 
developed OPC, and 73 patients did not present with OPC. 
Candidemia patients
Patients were enrolled after informed consent (or waiver as approved by the 
Institutional Review Board) at the Duke University Hospital (DUMC, Durham, NC, 
USA) and Radboud University Medical Center (RUMC, Nijmegen, The Netherlands). 
The study was approved by the Institutional Review Boards at each study center, and 
enrollment occurred between January 2003 and January 2009. To be included in the 
analysis of susceptibility to infection, infected subjects must have had at least one 
positive blood culture for a Candida species while hospitalized at the participating 
center. Non-infected controls must have been hospitalized with no history or evidence 
of candidemia/invasive candidiasis, or any invasive fungal infection. Non-infected 
controls were recruited from the same hospital wards as infected patients in such a 
way that comorbidities and clinical risk factors for infection would be similar between 
groups. The clinical characteristics of the patients have been previously reported in 
genetic association studies [9, 24, 30].
Genetic analysis
Genomic DNA was isolated from whole blood using standard procedures. Genotyping 
for the ATG16L1 T300A (rs2241880) and the IRGM SNPS (rs13361189 and rs4958847) 
single nucleotide polymorphisms (SNPs) was performed by using the TaqMan sin-
gle-nucleotide assay C_9095577_20, C_31986315_10 and C_1398968_10, respectively, 
on the 7300 ABI Real-Time polymerase chain reaction system (all from Applied 
Biosystems, CA, USA). Two of these polymorphisms (rs2241880 and rs4958847) were 
also part of the Sequenome (Sequenom MassARRAY®, Sequenom, San Diego, CA) 
analysis of the study of Smeekens at al [24]. However, we chose to assess it in the 
present study through TaqMan technology in the candidemia cohort, due to the fact 
that the quality of DNA necessary for Sequenome analysis was not sufficient for the 
entire cohort of patients. The assessment of all three polymorphisms in the studies 
on mucosal forms of infections has not been presented elsewhere.
Cytokine stimulation assays
Peripheral blood mononuclear cells (PBMC) were isolated from 73 healthy volunteers 
by Ficoll-Paque gradient. Subsequently, stimulation with heat-killed Candida albicans 
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blastoconidia was performed for 24 hours, 48 hours or 7 days. The stimulation time 
varied for each cytokine, being 24 hours for IL-1β, IL-6, IL-8 and TNFα, 48 hours for IFNγ 
and IL-10, and 7 days for IL-17. At the end of the incubation time, the above-mentioned 
cytokines were measured in the supernatants by ELISA (purchased from R&D systems 
Minneapolis, MN, or Sanquin Research, Amsterdam, The Netherlands). Comparisons 
of cytokine production between patients bearing the different ATG16L1 or IRGM 
genotypes were performed.
Serum cytokine measurements 
Cytokine concentrations of IL-6, IL-8 and IFNγ in plasma and serum samples obtained 
from infected patients from day 0 up to day 5 after initial positive blood culture were 
measured by Multiplex Fluorescent Bead Immunoassays (xMAP technology, Bio-Rad, 
Veenendaal, The Netherlands) and a Bio-plex microbead analyzer (Luminex, Austin, 
TX, USA) according to the manufacturer’s protocol.
Bioinformatic analysis
In order to predict the effect on the conformation of the ATG16L1 protein given the T300A 
amino acid change we used HOPE (http://www.cmbi.ru.nl/hope/), a next generation 
web server that performs automatic mutant analysis. No homology model was produced 
because no template with enough identity to the ATG16L1 sequence exists [31]. The 
HOPE server assessment was only possible for the ATG16L1 SNP since it is the only SNP 
from this study that alters the amino acid sequence and the HOPE servers works 
exclusively in case of non-synonymous mutations and their effect on protein function. 
Statistical analysis
For the genetic analysis, statistical comparisons of frequencies were made between 
infected and non-infected patients (with either OPC or candidemia) by performing 
the Chi-square test with SPSS version 20 (IBM SPSS Statistics for Windows Version 
20.0. Armonk, NY: IBM Corp. For the analysis of the in vitro PBMC stimulation and in 
vivo serum cytokine measurements, a Kruskal-Wallis one-way ANOVA was performed 
with the use of GraphPad Prism version 4.00 (GraphPad Software, San Diego, CA, 
USA). Corrections for multiple testing have not been performed due to the absence of 
significant differences, and throughout the manuscript only uncorrected P-values are 
mentioned.
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Results
Functional analysis of cytokine profiles
The cytokines measured in the in vitro assays are chosen based on their role in the 
anti-Candida immune response: TNFα, IL-1β, IL-6, IL-8 and IL-10 to monitor the response 
of monocytes, and IFNγ and IL-17 as T-cell derived cytokines to monitor the activation 
of the Th1 and Th17 responses, respectively. A significant difference in C. albicans- 
induced cytokine production was observed between cells isolated from individuals 
with different ATG16L1 genotypes for production of TNFα (P = 0.0039) (Figure 1). 
However, no differences were observed in the production of IL-1β, IL-6, IL-8, IL-10, IFNγ 
and IL-17. In addition, the effect of the genotype of the IRGM gene on the in vitro 
cytokine production was evaluated. These analyses revealed that the only statistically 
significant effect of the rs13361189 genotype was observed for production of IL-8. 
However, Candida induced IL-8 production was not affected by the other SNP in IRGM. 
Furthermore, TNFα, IL-1β, IL-6, IL-10, IFNγ and IL-17 production were not affected by 
any of the two investigated SNPs in IRGM. 
Bioinformatic Analysis using the HOPE server
We also performed a bioinformatic analysis using the HOPE next-generation server 
[31]. The output indicates that the change from a threonine into an alanine at position 
300 of the ATG16L1 protein introduces changes in the amino acid size and hydro-
phobicity. The mutant residue is smaller and more hydrophobic than the wild-type 
residue. Moreover, the server predicted that the polymorphism would cause an empty 
space in the core of the protein (or protein-complex). The change in the hydrophobicity 
between the wild-type and mutant-type amino acids would cause a loss of hydrogen 
bonds in the core of the protein (or protein-complex), and as a results it would disturb 
correct folding (Supplementary figure 1).
Oropharyngeal candidiasis 
The distribution of the ATG16L1 and IRGM polymorphisms in the HIV-positive patient 
groups with or without OPC is shown in Table 1. No statistically significant differences 
were observed. Since the CD4+ count is considered as a confounder, we stratified the 
study subjects based on their CD4+ counts. No significant association was observed in 
either CD4+ count group (Table 2).
Disseminated Candidiasis 
The intergroup comparison between the Dutch RUNMC and North-American 
Caucasian DUMC controls and patients revealed a similar genetic distribution of the 
genotyped SNPs, which allowed the groups to be merged into one group of subjects 
of European descent (data not shown). Genetic distribution of the ATG16L1 and IRGM 
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Figure 1   Functional analysis on the stimulation of peripheral blood mononuclear cells 
(PBMCs) with heat-killed C. albicans blastoconidia. Cytokine production capacity of 
TNFα, IL-1β, IL-6, IL-8, and IFNγ was compared between the cells obtained from 
healthy volunteers bearing wild-type or variant ATG16L1 or IRGM SNPs. Data are 
presented as means ± SEM, * p < 0.05. For the ATG16L1 rs2241880 polymorphism  
the antisense nucleotides are depicted.
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polymorphisms in the studied patient groups is shown in Table 3. No significant 
associations of polymorphisms in ATG16L1 and IRGM with susceptibility to candidemia 
were revealed (P>0.05).
Serum samples collected from patients with bloodstream Candida spp. infections 
during the first 5 days after initial positive blood culture were measured for concentrations 
of IL-6, IL-8 and IFNγ. The results are shown in Figure 2: IL-6, IL-8, and IFNγ circulating 
Table 1   Frequencies of the genotype of the ATG16L1 SNP number rs2241880 and the  
IRGM SNPs number rs13361189 and rs4958847 and the incidence of oropharyngeal 
candidiasis in HIV positive patients from Tanzania.
SNP OPC TT* (%) TC* (%) CC* (%) P-value
ATG16L1 rs2241880 Non-Infected (N = 73) 40 (54.79) 29 (39.72) 4 (5.48) 0.287
Infected (N= 81) 56 (69.14) 21 (25.93) 4 (4.94)
IRGM  rs13361189 OPC CC (%) CT (%) TT (%) 0.818
Non-Infected (N = 68) 14 (20.59) 36 (52.94) 18 (26.47)
Infected (N= 77) 17 (22.08) 35 (45.46) 25 (32.47)
IRGM rs4958847 OPC AA (%) AG (%) GG (%) 0.497
Non-Infected (N = 71) 14 (19.72) 39 (54.93) 18 (25.35)
Infected (N= 82) 22 (26.83) 42 (51.22) 18 (21.95)
Oropharyngeal candidiasis= OPC
* For the ATG16L1 rs2241880 polymorphism the antisense nucleotides are depicted.
Table 2   Minor Allele Frequencies of the ATG16L1 SNP number rs2241880 and the IRGM SNPs 
number rs13361189 and rs4958847 stratified by CD4+ count in a cohort of HIV positive 
patients from Tanzania.
CD4+ T cell count (minor allele frequency (%) OPC positive-OPC negative)
SNP <100 (N=40) 100-200 (N=81) 200-300 (N=26) >300 (N=5)
ATG16L1 rs2241880 16.67%-14.29% 33.33%-28.89% 20.00%-18.75% 0%-30%
IRGM  rs13361189 64.52%-50% 50%-51.22% 40%-53.33% 75%-80%
IRGM 
rs4958847
59.09%-50% 40.28%-46.67% 35%-63.33% 75%-87.5%
Oropharyngeal candidiasis= OPC
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concentrations were not affected by any of the SNPs in ATG16L1 and IRGM. Other 
cytokines such as TNFα, IL-1β, IL-10 and IL-17 were not detectable in the serum samples 
(data not shown).
Figure 2   Cytokine concentrations of IL-6, IL-8 and IFNγ in plasma and serum samples from 
infected patients from day 0 up to day 5 after initial positive blood culture correlated 
with the ATG16L1 or IRGM genotype. WT: wild-type, HET: heterozygous. HOM: 
homozygous. Data are presented as means ± SEM, * p < 0.05.
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Discussion
In the current study, we evaluated the effect of polymorphisms in the autophagy 
genes ATG16L1 and IRGM [15, 23] on the susceptibility to OPC and candidemia, 
respectively. Upon stimulation with Candida blastoconidia, the in-vitro cytokine 
production capacity of primary immune cells with different ATG16L1 genotypes 
demonstrated a lower production of TNFα by cells bearing the ATG16L1 300A allele. 
On the other hand, the variant allele of IRGM rs13361189 moderately increased IL-8 
Figure 2   Continued.
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production under similar conditions. Despite these differences, the genotype of the 
ATG16L1 and IRGM SNPs did not affect the susceptibility of patients to either OPC or 
systemic candidiasis. 
Genetic variation in genes coding for the autophagy regulatory proteins are known to 
alter the clearance of intracellular bacteria [23]. The SNP rs2241880 of ATG16L1 causes 
a partial loss of function in the ATG16L1 protein, inhibiting the Salmonella-induced 
autophagy process, which in turn results in reduced clearance of the microorganisms 
in human epithelial cells [15]. In addition, a polymorphism in the promoter region of 
the IRGM gene conferred an increased susceptibility to tuberculosis [32]. 21 different 
mouse IRG genes are located on chromosomes 11 and 18, and have been demonstrated 
to have a very powerful effect on the clearance of intracellular pathogens such as 
Listeria monocytogenes, Toxoplasma gondii [33, 34], Mycobacterium tuberculosis [35], 
Salmonella typhimurium and Chlamydia trachomatis [34]. Furthermore, genetic 
variation in both ATG16L1 and IRGM genes is associated with a higher susceptibility to 
Crohn’s disease [16-18, 22]. Conversely, the role of these genetic polymorphisms on 
the susceptibility to fungal pathogen has yet to be studied. Therefore, we have 
investigated whether SNPs in ATG16L1 and IRGM are related to the propensity to 
develop oropharyngeal and/or systemic Candida infections.
The effect of the T300A polymorphism on ATG16L1 function is the best characterized 
among the three SNPs evaluated in this study. The loss of function predicted with the 
HOPE server was evident on TNFα production, with a decrease paralleling the allelic 
dosage. This polymorphism is known to reduce autophagy [15], which is supported by 
a previous study [36]. Nevertheless, genetic variation in the ATG16L1 gene did not 
influence the susceptibility to either oropharyngeal or systemic candidiasis. 
In contrast to the ATG16L1 SNP, the IRGM polymorphisms evaluated in this study do 
not affect the IRGM protein sequence or structure, but modulate IRGM gene 
expression. McCarroll and colleagues demonstrated that IRGM haplotypes 
differentially affected gene expression in different cell types, and that the gene 
expression levels affected the efficiency of autophagy for eradicating intracellular 
bacteria [23]. Despite the possible consequences of the variation in the two IRGM 
SNPs, the genotype of either polymorphism did not affect the predisposition to 
oropharyngeal or systemic Candida infection.
The observation that the investigated SNPs in ATG16L1 and IRGM are not associated 
with increased susceptibility to Candida infections, but are involved in the pathogenesis of 
Crohn’s disease, may suggest that the link between Candida colonization and Crohn’s 
disease, through the presence of ASCA antibodies, is not mediated by autophagy. 
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However, one has to realize that the mechanisms underlying Candida colonization vs. 
Candida infection are largely different, as recently shown by our group [32]. Therefore, 
although autophagy appears not to be involved in susceptibility to Candida infection 
as demonstrated by the present study, it still could be associated with Candida 
colonization. Future studies are warranted to assess this aspect. 
Autophagy-mediated pathogen clearance is an important process mainly for host defense 
against intracellular bacteria such as mycobacteria or Salmonella typhimurium. Whereas 
of the role of autophagy in the clearance of extracellular bacteria has been 
demonstrated [37], the role of autophagy for anti-Candida albicans host defense remains 
unclear.  The lack of association of the SNPs in ATG16L1 and IRGM with susceptibility to 
Candida infections implies that host defense against Candida infections does not 
depend on these two genetic variants in autophagy genes. The results of the present 
study are strengthened by an additional report that showed that although Candida 
was able to induce autophagy in vitro, this was not necessary for host defense against 
disseminated candidiasis in mice [24]. Moreover, a set of polymorphisms in autophagy 
genes did not modulate susceptibility to candidemia [24]. The complementary results 
of these investigations strongly argue that autophagy is a redundant mechanism for 
host defense against both systemic and mucosal Candida infections.
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Supplementary Figure 1  Bioinformatics analysis of the consequences of the SNP number 
rs2241880 in ATG16L1. A comparison was performed between the wild type threonine residue 
and the mutant type alanine residue at the position 300 of the protein. The server is available 
at: http://www.cmbi.ru.nl/hope/home.
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Abstract
Opportunistic infections are the main cause of morbidity and death among 
HIV-positive patients. Most of these infections are linked to the immunodeficiency 
due to low CD4+ counts. However, not all patients with low CD4+ counts are equally 
susceptible to infections, and we hypothesize that variability in genes of innate 
immunity may also play an important role. The dectin-1/CARD9 pathway is crucial for 
recognition of both fungal and bacterial pathogens. The aim of this study was to 
assess the possible association between the occurrence of opportunistic infections 
and single nucleotide polymorphisms in DECTIN-1 and CARD9 in a cohort of 187 
HIV-infected patients. The incidence of oropharyngeal candidiasis and other 
opportunistic infections was not influenced by either the Y238X DECTIN-1 or the S12N 
CARD9 polymorphism. Surprisingly however, the prevalence of pneumonia was 
significantly higher in patients bearing the defective variant DECTIN-1 allele. These 
results suggest a role of dectin-1 in the host defense against respiratory bacterial 
infections, and future studies are warranted to confirm this association.
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Introduction
Opportunistic infections caused by a large variety of viral, bacterial and fungal 
pathogens are the main cause of morbidity and death among HIV positive patients, 
and most of them are linked to the immunodeficiency due to the decrease in the CD4+ 
lymphocytes (<200 cells/µL) [1]. Oropharyngeal candidiasis (OPC), caused by the 
dimorphic yeast Candida albicans, is the most frequently observed infection among 
HIV-positive patients [2-11], 2006. Whereas the immunodeficiency predisposes to 
recurrence of OPC, this is not life-threatening [12]. However, untreated oropharyngeal 
candidiasis in HIV-infected patients may lead to more invasive diseases, including 
esophageal [13] or even systemic candidiasis [14].
C. albicans is recognized by the innate immune system of the host by pattern 
recognition receptors such as TLR2, TLR4, mannose receptor and dectin-1 [15]. Dectin-1 
belongs to the C-type lectin receptor family, is present on dendritic cells, neutrophils 
and macrophages and recognizes β-1,3-glucan molecules on the cell wall of C. albicans 
and other fungi [16]. Moreover, the ability of the dectin-1 receptor to synergize with 
TLR2 and TLR4 promotes pro-inflammatory cytokine production and induction of Th1 
and Th17 mediated host defense against C. albicans [17, 18]. In addition, dectin-1 seems 
to be also involved in recognition of bacterial pathogens such as mycobacteria [19].
An early stop codon polymorphism in the DECTIN-1 gene leads to a truncated dectin-1 
protein at amino acid position 238 [20]; hence, the mutant protein is ten amino acids 
shorter than the wild-type and this results in defective β–glucan recognition and 
decreased induction of Th17 responses. Clinical manifestations of individuals 
homozygous for the 238X allele include recurrent vulvovaginal candidiasis and 
onycomycosis [20]. Moreover, the mutant allele of this polymorphism is also 
associated with a higher susceptibility to mucosal colonization with Candida spp. in 
patients undergoing stem cells transplantation [21].
CARD9 (caspase recruitment domain family member 9), the adaptor protein of both 
the dectin-1 pathway and the peptidoglycan recognition receptor NOD2, links 
intracellular signals with Bcl10-Malt1-dependent NF-κB activation. Rare mutations in 
CARD9 have also been identified as the cause of increased susceptibility to Candida 
infections [22]. Moreover, a common genetic variant of the CARD9 gene, a substitution 
of a guanine with an adenine residue, has also been described in the human HapMap 
database and the 1000 genomes project database. This results in an amino acid 
change from a serine to an asparagine residue on position 12 of the protein [23]. So far no 
studies have assessed the impact of this polymorphism on susceptibility to infections.
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The potential role of polymorphisms in DECTIN-1 and CARD9 for the susceptibility of 
HIV patients to infections is unknown. The aim of this study was to assess whether 
DECTIN-1 and CARD9 polymorphisms are associated with opportunistic infections in a 
cohort of 187 HIV-seropositive patients.
Materials and Methods
Patients
We evaluated a cohort of 187 HIV positive patients under follow-up at the Out-patients 
Department of Special Infections of the Attikon University General Hospital of 
Athens. Patient samples and clinical information were collected after informed 
consent and the study was approved by the institutional review board. CD4+ cell 
counts were measured by flow cytometry using microspheres and viral load by 
real-time PCR. Infections were diagnosed according to the CDC definitions. The 
causative pathogens for pneumonia could not be identified retrospectively. Empirical 
treatment with good clinical effectiveness was administered for both Streptococcus 
pneumoniae and atypical pathogens.
Genotyping of DECTIN-1 and CARD9 polymorphisms
Genomic DNA was isolated from whole blood using standard procedures. The genotype 
for the DECTIN-1 Y328X (rs16910526) and CARD9 S12N (rs4077515) polymorphisms in the 
patients was screened by the TaqMan SNP assay C_33748481_10 and C_25956930_20, 
respectively, on the 7300 ABI Real-Time polymerase chain reaction system (Applied 
Biosystems, CA, USA). Positive and negative controls were included in the assays.
Bioinformatic Analysis
To predict the effect on the conformation of the CARD9 protein given the S12N amino 
acid change, we used HOPE (http://www.cmbi.ru.nl/hope/), a next generation 
bioinformatics web server that performs automatic mutant analysis. No homology 
model was produced because no template with enough identity to the CARD9 
sequence exists [24]. More information can be found on http://www.cmbi.ru.nl/–
hvensela/CARD9/. We also used the Polyphen software in order to determine 
quantitatively the damage for the protein stability taking into account the amino 
acid change of the CARD9 SNP [25], and the SIFT server to predict whether the 
polymorphism was tolerated or not for protein function [26].
Statistical Analysis
For the analysis of SNPs, statistical comparisons of frequencies were made between 
infected versus non-infected subjects using the Chi-square test by SPSS software. 
Bonferroni corrections were incorporated in these analyses.
5GENETIC VARIATION IN β-GLUCAN RECOGNITION AND OIS IN HIV PATIENTS
69
Results
Patient Characteristics
The clinical characteristics of the HIV patients are presented in a previous report by 
Papadopoulos and colleagues [27] and are listed in Table 1. The nadir CD4+ count and 
the peak viral load did not differ among the DECTIN-1 and CARD9 genotypes, thus it 
was not considered as a confounder.
Fungal Infections
Statistical comparisons were performed to assess the association of the DECTIN-1 and 
CARD9 polymorphisms with the occurrence of fungal or bacterial opportunistic 
infections (Table 2). Because dectin-1 is mainly a fungal recognition receptor, we 
initially assessed the incidence of the genotype of the DECTIN-1 and CARD9 
polymorphisms on the occurrence of the fungal infections oropharyngeal candidiasis 
(OPC), Pneumocystis carinii pneumonia (PCP) and cryptococcosis, which revealed no 
statistically significant differences. Similarly, when oropharyngeal candidiasis was 
considered separately from the other fungal infections, no significant differences 
were observed with either the DECTIN-1 or with the CARD9 polymorphism.
Table 1   Clinical characteristics of HIV patients.
SNP Characteristic Homozygous Heterozygous Homozygous P-value
DECTIN-1 
Y238X
Male/Female 73/11 61/19 20/4 0.266
CARD9 S12N 131/30 22/3 1/0 0.647
DECTIN-1 
Y238X
Age (years, 
mean ± SD)
41.6 ± 12.1 41.6 ± 10.3 38.5 ± 10.2 0.414
CARD9 S12N 41.2 ± 10.9 42.0 ± 12.9 42 0.409
DECTIN-1 
Y238X
Nadir CD4+ 
count (/mm3 , 
median-range)
266 (8-658) 259 (1-624) 195 (6-525) 0.370
CARD9 S12N 252 (1-658) 261 (12-525) 250 0.430
DECTIN-1 
Y238X
Maximum viral 
load
CARD9 S12N
(copies/ml, 
median-range)
66850  
(3127-3560000)
75041  
(470-1040000)
35399  
(2794-51000000)
0.855
CARD9 S12N 64395  
(470-5100000)
81847  
(5187-1040000)
750000 0.075
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To elucidate the impact of the studied genotypes on the occurrence of fungal 
infections in the event of decreased CD4+ cells, enrolled patients were divided into 
two subcategories according to their median CD4+ count, i.e., those with CD4+ more 
than 250/mm3 and those with CD4+ less than or equal to 250/mm3. No differences 
were found in the occurrence of fungal infections between genotypes when the CD4+ 
count was below the median value (data not shown). No effects of the DECTIN-1 and 
CARD9 genotypes on the CD4+ counts were observed. 
Bacterial Infections
Dectin-1 has also been described to be involved in recognition of Mycobacterium 
tuberculosis [19], and CARD9 is an adaptor molecule also for the NOD2 recognition 
pathway of bacterial peptidoglycans [28]. Therefore, we hypothesized that the 
occurrence of bacterial opportunistic infections may be related to the genotype of 
the DECTIN-1 and CARD9 polymorphisms. Interestingly, these analyses revealed 
increased susceptibility towards bacterial infections of patients heterozygous for the 
DECTIN-1 polymorphism (Table 2). In contrast, no association was found between the 
CARD9 SNP and the occurrence of bacterial infections. Within the group of bacterial 
infections, DECTIN-1 was significantly associated with pneumonia, of which three 
patients had pneumococcal bacteremia, two among heterozygous patients and one 
among homozygous patients of every allele. No association between the tested 
polymorphisms and syphilis or salmonellosis was observed.
Discussion
In the present study, we demonstrate that heterozygosity for the Y238X DECTIN-1 
polymorphism in HIV-infected patients predisposes to bacterial infections, and in 
particular to pneumonia. In contrast, variation in the DECTIN-1 and CARD9 genes was 
not associated with susceptibility to opportunistic fungal infections in HIV-positive 
patients.
These findings are somehow unexpected. Because polymorphisms in PRRs are 
associated with a higher incidence of fungal and bacterial infections [29, 30] it was no 
surprise that genetic variants of DECTIN-1 and CARD9 were reported to increase the 
susceptibility to mucocutaneous fungal infections [20, 22]. This leads to the question 
how the lack of an effect of genetic variants of DECTIN-1 and CARD9 on opportunistic 
fungal infections in HIV patients is to be explained. Firstly, although the variant allele 
of the DECTIN-1 Y238X polymorphism results in a loss-of-function of dectin-1 and 
consequently of IL-6 and IL-17 production [20], this defect is only partial in the case of 
DECTIN-1 heterozygosity.Ta
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In the present study, HIV seropositive patients heterozygous for the DECTIN-1 Y238X 
polymorphism do not display an increased susceptibility to develop fungal infections, 
indicating that a partial dectin-1 deficiency is possibly redundant within this context. 
It could be also hypothesized that the basic defect in HIV patients, the lack of CD4+ 
cells, already results in a defective IL-17 and IL-22 production, and this has an overriding 
influence. Second, one has to observe also the subtle differences between the 
localization of the fungal infections in HIV and dectin-1-deficiency patients: 
oropharyngeal cavity, and vulvo-vaginal, respectively. Thus, although dectin-1 is 
known to be expressed on epithelial cells [31], differences in the pathogenesis of OPC 
on the one hand and recurrent vulvo-vaginal candidiasis on the other hand, may 
explain why polymorphisms in DECTIN-1/CARD9 may be important for the latter, but 
not for the former.
Third, another possibility to explain the lack of effect of DECTIN- 1/CARD9 polymorphisms 
on susceptibility to fungi is that the alternative β-glucan receptors, including the 
complement receptor 3, scavenger receptors, and CD5 [32, 33] may also recognize the 
fungi and induce host defense mechanisms. Finally, one also has to observe that the 
relatively low number of patients may also be a factor contributing to the lack of 
effects, and future studies are warranted to enable to draw a definitive conclusion.
T-cell immunity is crucial for antimicrobial host defense. A threshold number of CD4+ 
T cells is required to protect the host, and under that threshold host defense relies 
predominantly on innate host defense mechanisms [34-37]. We hypothesized that a 
genetic deficiency in the innate immunity may surface more prominently in HIV 
patients than in immunocompetent patients, due to the defective T-cell responses. In 
line with these arguments, a positive association between the DECTIN-1 polymorphism 
and the prevalence of pneumonia was found in the HIV-infected patients. Pneumonia 
is an inflammatory condition of the lung that can be caused by viral, fungal or 
bacterial pathogens.
Both the innate and the adaptive immune system are involved in the protection 
against the causal agents of pneumonia, and the increased prevalence of pneumonia 
in the hyper-IgE syndrome patients with STAT3 mutations demonstrated an important 
role of the Th17 produced cytokines IL-17 and IL-22 in host defense during bacterial 
pneumonia [38, 39]. IL-17 is involved in granulopoiesis and neutrophil recruitment 
[40], while IL-22 induces the production of β-defensins that improve the mucosal host 
defense against pathogens [41, 42].
Finally, IL-22 stimulates the lung endothelium regeneration and increases transepi-
thelial resistance to injury [43]. It is important to underline one more time that it is 
likely that this effect of the DECTIN-1 polymorphism on susceptibility to pneumonia is 
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exerted mainly in conditions in which CD4+-dependent mechanisms are defective, as 
no increase in the susceptibility to pneumonia has been observed in dectin-1 deficient 
patients with a normal T-cell immunity [20].
No relation was found between the occurrence of salmonellosis and syphilis and the 
genotype of the DECTIN-1 Y238X polymorphism, but that may be related to the low 
number of infections with these microorganisms in the present study. However, due 
to the low prevalence of fungal infections in our cohort, at this stage it is not possible 
to draw definitive conclusions regarding the role of these polymorphisms on the 
susceptibility to fungal infections. However, the cohort provided sufficient power for 
the analysis of bacterial infections in relation to the host genotype (data not shown).
Several explanations may be the cause of the lack of an association of the CARD9 S12N 
SNP with susceptibility to opportunistic infections. Since the consequences of the 
presence of the CARD9 polymorphism for its function have not been studied, one 
possibility is that this polymorphism affects only minimally the protein structure and 
function. Radboud University Nijmegen created the next generation bioinformatics 
server HOPE, which can predict the changes in protein structure given an amino acid 
change. Despite the lack of the homology model, the output of the server yielded that 
the mutation is located within the “CARD” domain (caspase recruitment domain). 
Although the mutation introduces an amino acid with changed hydrophobicity of the 
wild-type and mutant aminoacids, and the mutation causes loss of hydrophobic 
interactions in the core [24], the Harvard University’s Polyphen server predicts the 
effect of the serine to asparagine amino acid change as benign for its protein function 
[25], and the SIFT output show the polymorphism to be tolerated by the protein [26]. 
These bioinformatic tools have a high reliability based on sufficient sensitivity and 
specificity values (File S1).
In conclusion, the present study is the first to report the role of genetic variation in 
the dectin-1/CARD9 pathway in relation with the susceptibility to opportunistic 
infections in immunocompromised HIV patients, which revealed an association of 
the DECTIN-1 polymorphism with pneumonia. Further studies are warranted to 
confirm this association and to decipher the precise mechanisms through which this 
effect is exerted.
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Supplementary Figure 1  Output of the Polyphen server and multiple sequences alignment 
at the position 12 of the CARD9 protein regarding the S12N amino acid change of the SNP 
number rs4077515.
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Supplementary Figure 2  Output of the SIFT server regarding the S12N aminoacid change of 
the SNP number rs4077515.
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Supplementary Figure 3  Output of the HOPE server regarding the S12N aminoacid change 
of the SNP number rs4077515.
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CHAPTER 6
Gene Polymorphisms in  
Pattern Recognition Receptors and 
Susceptibility to Idiopathic Recurrent 
Vulvovaginal Candidiasis
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Abstract
Objective. Approximately 5% of women suffer from recurrent vulvovaginal candidiasis 
(RVVC). It has been hypothesized that genetic factors play an important role in the 
susceptibility to RVVC. The aim of this study was to assess the effect of genetic 
variants of genes encoding for Pattern Recognition Receptors (PRRs) on susceptibility 
to RVVC.
Study design. For the study, 119 RVVC patients and 263 healthy controls were recruited. 
Prevalence of polymorphisms in five PRRs involved in recognition of Candida were 
investigated in patients and controls. In silico and functional studies were performed 
to assess their functional effects. 
Results. Single nucleotide polymorphisms (SNPs) in TLR1, TLR4, CLEC7A and CARD9 did 
not affect the susceptibility to RVVC. In contrast, a non-synonymous polymorphism 
in TLR2 (rs5743704, Pro631His) increased the susceptibility to RVVC almost 3-fold. 
Furthermore, the TLR2 rs5743704 SNP had deleterious effects on protein function as 
assessed by in-silico analysis, and in-vitro functional assays suggested that it reduces 
production of IL-17 and IFNγ upon stimulation of peripheral blood mononuclear cells 
with C. albicans. No effects were observed on serum MBL concentrations.
Conclusion. Genetic variation in TLR2 may significantly enhance susceptibility to 
RVVC by modulating host defense mechanisms against Candida. Additional studies are 
warranted to assess systematically the role of host genetic variation for susceptibility 
to RVVC. 
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Introduction
Candida microorganisms, especially C. albicans, often colonize the genital tract in 
women, and under certain conditions are responsible for mucosal inflammation [1-6]. 
Vulvovaginal candidiasis (VVC) is a frequent consequence of Candida infection, 
accompanied by variable pruritus, soreness, rash, and vaginal discharge, with patients 
experiencing a strong discomfort. Most women have at least one event of VVC in 
their lifetime, while up to 5-8% suffer from recurrent vulvovaginal candidiasis (RVVC), 
defined as at least three infections per year [4, 6]. 
Known risk factors of vulvovaginal candidiasis include diabetes, pregnancy and therapy 
with glucocorticosteroids, immunosuppressive drugs, and antibiotics [7-9]. However, 
the vast majority of RVVC patients are healthy women without any identifiable 
predisposing or episode precipitating factors [7, 8, 10-12]. Moreover, no distinct C. 
albicans strains, the species that causes more that 90% of the VVC episodes, have 
been described in RVVC patients, arguing against microbiological factors as the major 
determinants of VVC or susceptibility to recurrent disease [8, 12]. Thus, it has been 
hypothesized that host genetic factors may be a major component determining 
susceptibility to RVVC.
The innate immune system provides the first barrier against vulvovaginal Candida 
infection. Pattern recognition receptors (PRRs) on innate immune cells sense molecular 
moieties on the surface of microorganisms, and thereafter induce an intracellular 
signal that stimulates production of effector molecules such as cytokines or defensins. 
Two classes of PRRs have been reported to be the main recognition receptors for 
C. albicans: Toll-like receptors (TLRs) and C-type lectin receptors (CLRs) [13].  TLR4 
recognizes fungal cell wall mannans, while TLR2/TLR1 and TLR2/TLR6 heterodimers 
recognize Candida phospholipomannan [14]. Additionally, TLR2 synergizes with 
DECTIN-1, the receptor for β-glucan, for the induction of proinflammatory cytokines 
[15, 16]. DECTIN-1 can also induce TLR-independent signals for the production of IL-17, 
IL-6 and IL-10 through a Syk/CARD9-dependent pathway [17]. Single nucleotide 
polymorphisms (SNPs) in both TLRs and C-type lectin-like receptors (CLRs) have been 
described to be associated with an increased susceptibility to both systemic [18] and 
oropharyngeal [19] candidiasis, and we hypothesized that similar effects may be 
exerted on the susceptibility to RVVC.
The aim of this study was to assess the impact of the SNPs in the genes coding for 
DECTIN-1 (Tyr238X, rs16910526), CARD9 (Ser12Asn, rs4077515), TLR1 (Arg80Thr, rs5743611), 
TLR2 (Pro631His, rs5743704) and TLR4 (Asp299Gly, rs4986790; Thr399Ile, rs4986791) 
on the susceptibility to RVVC. 
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Materials and Methods
Ethics statement
The inclusion of patients and controls in this study was approved by the Institutional 
Review Boards of the Radboud University Medical Centre, Wayne State University 
School of Medicine and Hôpital Necker. Enrollment took place between January 2010 
and December 2011. Patients gave written informed consent and the study in 
accordance to the declaration of Helsinki.
Enrolment of healthy controls for blood donations was approved by the Institutional 
Review Board of the Radboud University Medical Centre.
Patients and control subjects
The patient cohort consisting of RVVC patients were recruited at Wayne State 
University School of Medicine (Detroit, MI, USA), Radboud University Nijmegen 
Medical Center (Nijmegen, The Netherlands) and Hôpital Necker (Paris, France). 
Patients were enrolled during episodes of acute vaginitis or, if asymptomatic, while 
receiving maintenance fluconazole therapy. Inclusion criteria for the study were: 
healthy women above 18 years of age, diagnosed with at least three documented 
episodes of VVC in a year, microbiologically validated and all caused by C. albicans. 
Exclusion criteria were use of any immunosuppressive therapy (including steroids), 
diabetes, pregnancy and HIV infection. EDTA venous blood was collected after 
obtaining written informed consent. Asymptomatic healthy controls without a 
history of vaginal Candida infections (N=263) were recruited at Radboud University 
Nijmegen Medical Center, Nijmegen, The Netherlands and gave written informed 
consent. All patients and controls were of Western-European genetic background.
Genotyping of the single nucleotide polymorphisms (SNPs)
Genomic DNA was isolated from whole blood using the Qiagen (Valencia, CA, USA) 
isolation kit 6 and following the standard protocol. The genotype for the CLEC7A 
(DECTIN-1) Tyr328X (rs16910526) and CARD9 Ser12Asn (rs4077515) polymorphisms in 
the patients was screened by the TaqMan SNP assay C_33748481_10 and 
C_25956930_20, respectively (Applied Biosystems, Foster City, CA, USA). The 
genotype for the TLR1 polymorphism Arg80Thr (rs5743611) was assessed with the 
TaqMan SNP assay C_27855269_10. The genotype of TLR2 Pro631His (rs5743704) was 
assessed by applying a predesigned TaqMan SNP assay C_25607736_10. The 
genotyping for the TLR4 polymorphisms Asp299Gly (rs4986790) and Thr399Ile 
(rs4986791) was performed with the TaqMan SNP assay C_11722238_20 and 
C_11722237_20, respectively. The TaqMan qPCR assays were performed on the 7300 
ABI Real-Time polymerase chain reaction system (Applied Biosystems). Positive and 
negative controls were included in the assays.
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Bioinformatic analysis for the TLR2 polymorphism rs5743704 
The TLR2 protein information was obtained from Swissprot accession code O60603, 
and OMIM accession code 603028, using the MRS server (http://mrs.cmbi.ru.nl/
mrs-web). We used the PROSITE server (http://expasy.org/prosite) to retrieve 
information about the TLR2 protein domains. No protein structure is available for the 
complete TLR2 protein at the moment. However, the cytoplasmic TIR domain is 
known and can be found as PDB-file 1O77 [20]. This structure in this file contains a 
mutation on position 713 and misses one loop, but the remaining residues are 100% 
identical to the sequence of TLR2.
The extracellular domain up to residue 509 is 100% identical to the protein in PDB file 
2Z7X [21]. The Pro631His polymorphism is located in the region linking the TIR domain 
with the intracellular domain. We used the automatic modeling script in the YASARA 
& WHAT IF Twinset [22] to extend the known structures and to model missing loops 
in these structures. As a result, we produced models of the N- and of the C-terminal 
domain, which are both accurate, because they are based on the known structure of 
that protein. These structures are extended with residues of the linking region. 
Additionally, we used HOPE (http://www.cmbi.ru.nl/hope), a next generation 
bioinformatics web server that performs automatic mutant analysis [23]. Besides 
this, an analysis of the pathogenicity of the Pro631His polymorphism in TLR2 was 
performed using conservation and structural information. The Polyphen-2, SIFT, 
PANTHER, snps3D and the SNAP servers where employed for this analysis. 
Cytokine stimulation assays
Peripheral blood mononuclear cells (PBMC) were isolated from 73 healthy volunteers 
by Ficoll-Paque gradient. All healthy volunteers gave written informed consent. 
0.5x10^6 PBMCs/well were plated in round bottom wells plates. Subsequently, 
incubation with Candida albicans blastoconidia (1x106/ml, heat-killed at 100°C for 1h) 
was performed for 24 hours, 48 hours or 7 days. The incubation time varied for each 
cytokine: 24 hours for IL-1² and IL-6, 48 hours for IFNγ and IL-10, and 7 days for IL-17 
(with the addition of 10% human serum). After the incubation time, cytokines were 
measured in the supernatants by ELISA (R&D Systems, MN, USA or Sanquin Research, 
Amsterdam, The Netherlands). Detection limits were 40 pg/mL, except for the IFNγ 
ELISA (12 pg/mL). Mannose binding lectin (MBL) concentrations in serum were 
measured by ELISA (Bioporto, Gentofte, Denmark).
Statistical analysis
For the analysis of the polymorphisms in the PRRs, statistical comparisons of 
frequencies were made between RVVC versus control subjects. We used SPSS 16.0 
software to perform Chi-square tests and the 5% Confidence Intervals Odds ratio to 
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calculate the risk. Furthermore, for the analysis of the effect of the TLR2 genotype on 
the in vitro cytokine production, a non-parametrical Kruskal-Wallis analysis was 
performed, and for the circulatory MBL measurement we used the Mann-Whitney U 
test. Both analyses were done using GraphPad Prism version 4.00 for Windows, 
GraphPad Software, San Diego, CA, USA.
Results
The influence of polymorphisms in PRR genes on the susceptibility to RVVC 
As a polymorphism in the gene encoding the CLR DECTIN-1 (CLEC7A) has previously 
been shown to be associated with an increased susceptibility to fungal infections, a 
first set of comparisons assessed the prevalence of CLEC7A and CARD9 polymorphisms 
in control individuals and patients with RVVC (Table 1). No effects of CLEC7A (Tyr238X, 
rs16910526) and CARD9 (Ser12Asn, rs4077515) polymorphisms on the susceptibility 
to RVVC have been observed. In a second set of experiments, the prevalence of 
polymorphisms in the genes coding for TLR1 (Arg80Thr, rs5743611), TLR2 (Pro631His, 
rs5743704) and TLR4 (Asp299Gly, rs4986790; Thr399Ile, rs4986791) was also assessed. 
These analyses revealed that the polymorphisms in the TLR1 and TLR4 genes did not 
affect the susceptibility to RVVC. In contrast, the genotype for the Pro631His 
polymorphism on the TLR2 gene was associated with a 2.705-fold increase (P-value 
0.046) in susceptibility to RVVC in the patient cohort. All genetic distributions are in 
Hardy-Weinberg equilibrium (Table 1).
Bio-informatic analysis TLR2 rs5743704 polymorphism
Because the TLR2 Pro631His polymorphism was associated with an increased 
susceptibility to RVVC, the functional effects of this genetic variation were studied. In 
a first analysis, an in silico evaluation of the effect of the Pro631His polymorphism on 
the TLR2 protein was performed. We evaluated its effect at the genomic level, by 
performing multiple sequence alignment of the homologous DNA sequences from 
35 other species via the Ensembl server. The cytosine base is conserved at the 
chromosome 4 nucleotide position 154625451, being also the ancestral allele, 
evolutionary conservation that underlines a high likelihood that this position in the 
molecule is functionally important. 
To analyze the effects of the single nucleotide polymorphism rs5743704 on the TLR2 
protein, we analyzed the possible domains identified via the Prosite server. The amino 
acid change for the Pro631His polymorphism affects an amino acid residue that is located 
near the TIR domain (residue 639-784). To visualize the Pro631His polymorphism on the 3D 
structure of the TIR domain, we evaluated the homology model using the YASARA 
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software. A screenshot of the 3D homology model is shown in Figure 1. The amino 
acid change is situated between the intracellular domain and the TIR domain, and 
might introduce a loss in rigidity when substituting proline by histidine.
Finally, the HOPE server predicted that due to the fact that the polymorphism 
introduces an amino acid with different characteristics, this would affect the function 
of the molecule. The wild-type residue proline is rigid, resulting in a characteristic 
backbone conformation that might be required at this position. Additionally, proline 
is more hydrophobic than histidine, and this may also influence the function of the 
molecule through loss of hydrophobic interactions on the surface of the protein. This 
hypothesis was also tested through a series of web servers to predict the pathogenicity 
of the Pro631His amino acid change. As shown in Supplementary Table 1, according to 
the Polyphen-2, SIFT, PANTHER and snps3D, the effect of the Pro631His polymorphism 
is predicted detrimental for TLR2 function.
Figure 1   Screenshot of the 3D homology model of the TLR2 protein using the YASARA 
software. The side chains of the wild-type and mutant residues are shown in green 
and red respectively.
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The effect of the TLR2 Pro631His polymorphism on the production of 
inflammatory mediators
In order to assess the functional consequences of the TLR2 Pro631His polymorphism 
in further detail, cytokine production of PBMCs stimulated with heat-killed Candida 
albicans was assessed in a group of healthy volunteers. The major limitation of this 
Figure 2   Functional analysis on the stimulation with heat-killed Candida albicans of 
peripheral blood mononuclear cells (PBMCs) with different TLR2 Pro631His 
genotypes. Cytokine production capacity of TNFα, IL-1β, IL-6, IL-10, IL-17 and IFN-γ was 
compared between the cells obtained from healthy volunteers bearing the wild-type 
or the variant allele of the TLR2 polymorphism. D1: Donor 1, D2: Donor 2. Data are 
presented as means ± SEM.
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part of the study was that only 2 individuals in this group were heterozygous for the 
variant allele, which precludes drawing definitive conclusions. However, we observed 
that whereas the IL-1β, IL-6, and TNFα production was in the same range comparing 
the different genotype groups, both individuals bearing the mutated allele displayed 
a strongly diminished release of the T-cell derived cytokines IFNγ and IL-17 (Figure 2), 
known to be important for antifungal host defense [24-26]. In contrast, MBL 
circulating concentrations in the RVVC patients did not differ depending on the TLR2 
genotype (Figure 3).
Discussion
Vulvovaginal candidiasis is one of the most common infections in women. Despite 
known risk factors such as the hormonal status, diabetes, pregnancy or immunosup-
pressive therapy [7-9, 12, 27], the majority of the patients are healthy women who are 
not exposed to these conditions. In the present study, we explored whether genetic 
variation in genes coding for PRRs involved in Candida recognition [14] affects 
susceptibility to RVVC. We show that a non-synonymous polymorphism in TLR2 is 
associated with increased susceptibility to RVVC. In-silico assessment suggested 
functional consequences of the TLR2 polymorphism, and this hypothesis is supported 
by the decreased production of T-cell derived cytokines IFNγ and IL-17 in two 
individuals bearing the mutation. However, a definitive conclusion was not able to be 
drawn due to the low number of volunteers with TLR2 SNP identified in the functional 
studies.
Figure 3   Analysis on the Mannose Binding Lectin (MBL) concentrations in serum obtained 
from RVVC patients bearing the wild-type or the variant allele of the TLR2 
poly morphism Pro631His. Wt: Wild-type, He: Heterozygous. Data are presented as 
means ± SEM.
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Genetic variants in PRRs have been previously reported to influence predisposition to 
RVVC. This has been described in a family of patients with a complete deficiency of 
DECTIN-1, due to an early stop codon mutation in the CLEC7A gene coding for the 
DECTIN-1 receptor [28]. Functional consequences of DECTIN-1 deficiency were 
demonstrated to include impaired induction of both innate and adaptive Th17 
immune responses. Furthermore, several other studies have shown the involvement 
of adaptive immunity in RVVC in humans [29, 30]. In addition to RVVC occurrence in 
two of the three patients with DECTIN-1 deficiencies, all suffered from onychomycosis. 
This mutation appears to be relatively common, up to 15% heterozygosity in 
populations of European origin, allowing epidemiological studies in heterozygous 
patients [28]. Moreover, heterozygosity in  the CLEC7A gene is associated with 
increased mucosal Candida colonization [31]. Thus, we assessed its impact in the 
present study. The loss of one functional allele, however, does not seem to have a 
major impact on the susceptibility to RVVC. This implies that only a complete loss-of-
function in the molecule is associated with a significant risk for infection. In addition, 
it has also recently been shown that this polymorphism does not affect the 
predisposition to disseminated Candida infections [31, 32].
CARD9 is an adaptor molecule mediating signals induced by DECTIN-1, but also other 
C-type lectin receptors. Its role in antifungal immunity has been demonstrated both 
in knock-out mouse studies [33], as well as by the increased susceptibility to severe 
fungal infections in patients defective in this molecule due to an early stop codon in 
position Gln295Stop [34]. However, this mutation is rare and has not been reported in 
other individuals. The evaluation of the effects of a known CARD9 Ser12Asn 
polymorphism did not yield a significant association with RVVC susceptibility in the 
present study. Similarly, we have previously shown that this polymorphism does not 
influence the susceptibility to candidemia [32].
In addition to C-type lectin receptors, TLRs are the second major family of PRRs 
involved in the recognition of fungi in general, and Candida in particular, TLR2, TLR4, 
and TLR1 being most important in antifungal immunity [35]. While TLR1 polymorphisms 
have been recently shown to influence susceptibility to candidemia [18], no such 
effect was apparent in patients with RVVC. Similarly, two TLR4 polymorphisms that 
have been previously associated with susceptibility to gram-negative sepsis and 
other infections did not have a significant effect on susceptibility to RVVC [36].
In contrast, the TLR2 Pro631His polymorphism induced an almost 3-fold increase in the 
susceptibility to RVVC. TLR2 is an important PRR for C. albicans recognition, activating 
innate immune responses both alone and in synergy with DECTIN-1 [37]. The 
deficiency of TLR2 influences susceptibility to systemic candidiasis in mice [38], but no 
studies have been performed in vaginal candidiasis models. The in silico analysis 
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using homology modeling and conservation analysis suggests detrimental effects of 
the mutation on the function of the receptor. This is supported by the study of 
Etokebe and colleagues that the Pro631His polymorphism has a dominant negative 
effect on the TLR2 signaling in HEK-293T cells [39]. Finally, we studied the functional 
relevance of this polymorphism in primary cells from individuals bearing the various 
alleles. Although we were able to assess cytokine production in only two individuals 
with a mutant TLR2 allele, both of them consistently produced very low amounts of 
the T-cell derived cytokines IFNγ and IL-17, mediators that are crucial for mucosal 
antifungal defense [24, 28]. This observation is supported by the finding of Ben-Ali et al. 
who demonstrated that the 631His TLR2 variant leads to reduced NF-κB activation [40].
In addition to the effects of the TLR2 polymorphism on cytokine production, we have 
also assessed its influence on the concentrations of mannose-binding lectin (MBL). 
MBL is a circulating receptor for mannose residues which activates the complement 
system and opsonizes Candida [30]. MBL deficiency is associated with an increased 
susceptibility to RVVC [41, 42]. However, no differences in serum MBL concentrations 
were found between individuals bearing different TLR2 alleles, showing that the 
effect of the TLR2 Pro631His polymorphism on the RVVC susceptibility is independent 
of the production of MBL. Ideally, the cytokine analyses should be extended to 
assessment in lavage fluids or cells. However, these materials were not collected from 
the patients presented in this manuscript, and future studies should address this 
aspect.
In conclusion, in this study we provide evidence that polymorphisms in PRRs may play 
an important role in susceptibility to RVVC in otherwise healthy women. While 
CLEC7A, CARD9, TLR1 and TLR4 polymorphisms had no impact, the TLR2 Pro631His 
polymorphism was associated with an almost 3-fold increase in susceptibility to 
RVVC. These data demonstrate the role of TLR2 genetic variation in innate immunity 
genes for RVVC, and future investigations are warranted in larger cohorts if possible 
to replicate and extend the results of the present study. 
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Supplementary Table 1  Predictions on pathogenicity of the Pro631His polymorphism in the 
TLR2 gene using different web servers. 
Method URL Prediction Reference
Polyphen-2 http://genetics.bwh.harvard.edu/pph2/ Probably 
damaging
[42]
SIFT http://blocks.fhcrc.org/sift/SIFT.html Non-tolerated [43]
PANTHER http://www.pantherdb.org/tools/csnpScore.do Deleterious [44]
snps3D http://www.snps3d.org/ Deleterious [45]
SNAP http://cubic.bioc.columbia.edu/services/SNAP/ Non-neutral [46]

Adapted from : Journal de Mycologie Médicale. Volume 19, Issue 3 Pp. 191—196.
Diana Rosentul, Corine Delsing, Leo A.B. Joosten, Jos W.M. van der Meer, 
Bart-Jan Kullberg, Mihai G. Netea.
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Summary
Vulvovaginal candidiasis (VVC) is a clinical syndrome caused by vaginal yeast infection 
with Candida species (mostly C. albicans), characterized by itching, soreness, bright 
red rash, and heavy white vaginal discharge, causing a strong discomfort in patients. 
Recurrent vulvo-vaginal candidiasis (RVVC) is defined as the occurrence of at least 
three episodes of VVC per year. Predisposing factors such as pregnancy, the use of 
antibiotics, contraceptive pills or hormone replacement treatment and diabetes 
mellitus have been reported to contribute to the susceptibility for RVVC. Nevertheless, 
in most patients suffering from this debilitating disease, none of these risk factors are 
present. Therefore, it is believed that genetic predisposition may also play a significant 
role for the susceptibility to RVVC. The present review summarizes the current 
knowledge concerning the gene polymorphisms that have been associated with 
RVVC. Several components of the innate immune system related to the recognition of 
C. albicans (mannose binding lectin, Dectin-1), or the induction of inflammation (the 
cytokine interleukin-4, the NLRP3 component of the inflammasome, IDO and IL-22) 
have recently been shown to influence susceptibility to RVVC. However, further 
studies are warranted in order to understand more thoroughly the spectrum of 
genetic variation inducing genetic susceptibility to RVVC in otherwise healthy 
patients.
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Introduction
The dimorphic yeast Candida albicans inhabits the genital and gastrointestinal tract as a 
commensal microorganism [1-7]. However, under certain circumstances, C. albicans 
becomes a pathogen causing infections that can range from vulvovaginal candidiasis, 
to oropharyngeal candidiasis, and disseminated systemic infection [8]. The vast 
majority of women experience at least one episode of vulvovaginal candidiasis in 
their lifetime, while up to 5 to 8% of them will suffer from recurrent vulvovaginal 
candidiasis (RVVC), characterized by at least three infections per year. 
Most patients with candidemia or disseminated candidiasis are neutropenic or have a 
history of recent invasive procedures [9]. The risk factors of vulvovaginal candidiasis 
are different, with diabetes, pregnancy, HIV, glucocorticosteroid therapy, immuno-
suppressive therapy, or antibiotic therapy playing a role [10-15]. However, most 
patients with RVVC are healthy women without identifiable risk factors. It is believed 
that genetic factors are at least partly responsible for the increased susceptibility to 
RVVC. In the present review, we will summarize the current knowledge on the genetic 
polymorphisms predisposing to RVVC.
Vaginal immune response to Candida albicans and RVVC
C. albicans yeast cells are initially recognized by the innate immune system and 
epithelial cells (EC) [16]. Toll-like receptor (TLR) and lectin-like receptors (LR) families 
are the main classes of pattern-recognition receptors that recognize Candida 
components [17]. Both TLR4 and mannose receptor interact with cell wall mannans 
[18], while TLR2 recognizes phospholipomannan [19]. In addition, TLR2 collaborates 
with the β-glucan receptor dectin-1 for the stimulation of proinflammatory cytokines 
[20-22]. Dectin-1 is a C-type lectin receptor that amplifies TLR2 and TLR4-induced 
cytokine production in both murine and human cells, while inducing TLR-independent 
signals for the production of IL-17, IL-6, and IL-10 through a Syk-dependent pathway 
[23] (Fig. 1). 
In addition to the cell-membrane receptors, mannose-binding lectine (MBL) is a 
circulating protein that recognizes and binds mannose and N-acetyl-glucosamine 
residues on the surface of microorganisms, activating the complement system. The 
cells in the female genital tract that produce MBL have yet to be identified [24]. 
Furthermore, macrophages and dendritic cells contain cell surface receptors that 
recognize and bind MBL, promoting opsonization of MBL-bounded microorganisms 
[25]. Reductions in serum concentrations of MBL are commonly considered to 
contribute in some degree to susceptibility to infection, especially in the context of 
other defects of host defense [26].
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In healthy women, the main immunological defense mechanism against Candida is 
the cell-mediated mucosal Th1 response, and especially the proinflammatory 
cytokines interferon-γ (IFNγ), interleukin-17 and interleukin-22 are considered as 
major effector molecules [27, 28, 29]. The elimination of Candida is mediated by the 
recruitment and activation of macrophages, which respond to a proinflammatory 
cytokine response. Candida recognition and binding by mucosal macrophages is 
mediated by TLRs and CLRs, and possibly MBL. Stimulation of macrophages results in 
the synthesis of NO and oxygen radicals, compounds toxic for Candida.
Nitric Oxide (NO) is an important effector molecule of the innate immune defense 
against microorganisms [30]. However, its anti-Candida activity is strongly inhibited 
by IL-4, an anti-inflammatory cytokine with immunosuppressive effects. In addition, 
IL-4 blocks macrophage-mediated anti-Candida responses and the production of the 
Th1-derived proinflammatory cytokines [31, 32]. 
Figure 1   Innate host defense against C. albicans infection. Pattern recognition of C. albicans  
is mediated by recognition of mannans and β-glucans by TLRs and lectin receptors 
such as dectin-1 on the surface of the cell membrane, and the soluble mannose- 
binding lectin (MBL) extracellularly. These receptors induce production of cytokines, 
among which the anti-inflammatory IL-4 and the proinflammatory IL-1β. Processing 
and activation of IL-1β is performed by a protein complex called the inflammasome, 
that contains the NLR receptors NLRP3, ASC and caspase-1. Polymorphisms in MBL, 
dectin-1, IL-4 and NLRP3 have been associated with an increased susceptibility to RVVC.
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In addition to immune cells, C. albicans hyphae can also be detected by ECs, resulting 
in the production and release of proinflammatory cytokines (32). In addition, 
experimental evidences have shown that the interaction between ECs and C. albicans 
can impair its growth [34-36].
These host defense mechanisms are believed to be dysregulated in women suffering 
from RVVC. Defective mucosal defense mechanisms is likely to result either from a 
defective production of proinflammatory cytokines in response to Candida, or an 
overwhelming release of anti-inflammatory Th2-derived cytokines and prostaglandin 
E2 in the lower genital tract. A genetic propensity towards defective inflammatory 
responses, or towards the production of IL-4 and/or other anti-inflammatory mediators 
may thus decrease the capacity of the local cell-mediated immune system to contain 
Candida proliferation. It has been also proposed that this may lead to induction of a 
vaginal allergic response accompanied by histamine release and clinical symptoms [5, 
37-39]. A limited number of studies have investigated the role of genetic variability of 
the host for the susceptibility to RVVC. An overview of these studies are presented 
here, supporting a role for genetic variability in several genes of innate immunity 
such as MBL, IL-4, dectin-1 and NLRP3 for the vaginal mucosal infections with Candida.
Mannose Binding Lectin (MBL) Polymorphisms
A decrease in circulating MBL concentrations correlates with the presence of mutant 
alleles in exon 1 of MBL gene. The best-studied mutation is the single nucleotide 
mutation at base 230 of exon 1, causing a change of codon 54 from GGC to GAC [25, 
40, 41]. The substitution of glycine with an aspartic acid residue disrupts the fifth 
Gly-Xaa-Yaa repeat in the collagen-like domain of each 32 kD peptide chain and 
probably prevents the formation of the normal triple helix. As a result of this change, 
the assembly and stability of the final MBL protein decreases notably [25, 40, 41]. 
Serum concentrations of MBL are between 1.2  and 1.7 mg/mL in individuals who are 
homozygous for the wild-type (guanine) allele, 0.3mg/mL in individuals who are 
heterozygous, and 0.01 mg/mL in individuals homozygous for the variant allele 
(adenine) [30, 40-42]. The codon 54 substitution has been demonstrated to be 
accompanied by an increased rate of various infection [40, 43]. 
Babula and colleagues reported an association between RVVC and the carriage of the 
Gly54Asp polymorphism of MBL gene. The variant allele was also related to a 
reduction in the vaginal concentration of MBL. However, not all women with RVVC in 
this study carried the Gly54Asp variant allele, although the level of MBL in their 
vaginas was reduced. Arg52Cys, and Gly57Glu are other polymorphisms in exon 1 of 
the gene coding for MBL that have been identified to be associated with reduced 
circulating MBL concentrations [41, 44-46].
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There is some evidence linking the response to Fluconazol treatment in RVVC patients 
with the different genetic variation in codon 54, with the patients bearing the variants 
alleles more sensitive to the treatment [47]. Nevertheless, these findings are 
controversial since it has been suggested that there is no correlation between the 
Gly54Asp polymorphism and RVVC predisposition [48].
To conclude, the Gly54Asp MBL polymorphism may be a genetic determinant of 
susceptibility to RVVC in this population, but additional confirmation studies are 
needed.
Interleukin-4 (IL-4) Gene Polymorphism
IL-4 is one of the most important anti-inflammatory cytokines, and a high production 
capacity of IL-4 has been associated with immunosuppressive effects. Local vaginal 
IL-4 levels were higher and median NO levels were lower in patients with RVVC than 
in controls [24]. A single nucleotide polymorphism consisting of a cytosine to thymine 
variation in the promoter region of the IL-4 gene (C589T) has been reported [49], and 
this has been associated with increased IL-4 production by immune cells [50], and a 
12-fold increase in the vaginal concentration of IL-4. Similarly, there was a strong 
inverse relationship between vaginal concentration of IL-4 and MBL, as well as 
between the presence of the C589T allele and vaginal NO production. These factors 
are likely to influence susceptibility to RVVC [24].
 
Dectin-1 early stop-codon polymorphism
One of the most important pathogen recognition receptors for C. albicans is represented 
by the β-glucan receptor dectin-1 [22]. Recently, an early stop-codon mutation in position 
238 of the carbohydrate recognition domain (CRD) of dectin-1 has been described in a 
family of patients with RVVC and onycomycosis [51]. The mutated variant leads to the 
loss of the last nine aminoacids of the CRD domain, and as a consequence of two main 
stabilization structural features, a cysteine disulfide bridge between the helix and the 
deleted strand and the glutamic interaction with calcium atoms.
The Tyr238Stop allele results in the loss of β-glucan recognition and impaired cytokine 
response [51, 52]. Binding of heat-killed fluorescent-labeled C. albicans to monocytes 
was significant lower in those patients who were homozygous for Tyr238Stop 
mutation compared to healthy controls. Particularly, the proinflammatory cytokine 
IL-17 response to Candida stimulation was lower in patients bearing the mutation. 
This study also revealed that the amplification effect of β-glucan/dectin-1 interaction 
on the TLR2 stimulation of cytokines was absent in individuals homozygous for the 
mutation. On the other hand, monocyte and neutrophil phagocytic and candidacidal 
functions were normal in the presence of live C. albicans, both in healthy and in 
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homozygous Tyr238Stop individuals, showing the redundant nature of the mechanisms 
leading to the phagocytosis and killing of live yeasts.
In line with the increased risk for mucosal infections in these patients, the frequency 
of mucosal Candida colonization and infection in a cohort of hematologic patients 
undergoing stem cells transplantation was three times higher in patients bearing the 
dectin-1 Tyr238Stop allele. In contrast, dectin-1 Tyr238Stop polymorphism did not 
correlate with an increased susceptibility to systemic candidiasis [53]. A recent study 
also demonstrated that the early stop codon polymorphism in dectin-1 is correlated 
with a 2.4-fold increased susceptibility to RVVC [77], validating the involvement of 
this genetic variant in host defense against mucosal fungal infections.
NLRP3 gene polymorphism and susceptibility to RVVC
Vulvar vestibulitis syndrome (VVS), also known as vulvodynia, consists of an intense 
pain syndrome confined to the vaginal vestibule, which is defined as erythema and 
pain during introduction of a vaginal tampon, while touching the vagina with a 
cotton swab, as well as during gynecological examination or sexual intercourse. The 
causes of this condition and possible therapy have not yet been clarified, but a 
relationship between VVS symptom initiation and vaginal infection with C. albicans 
has been proposed [54]. C. albicans infections in the mucosa leads the proinflamma-
tory cytokine formation by epithelial cells for inactivation by phagocytic cells, and 
this may play a role in the local inflammatory reactions [33]. 
The ‘‘inflammasomes’’ are macromolecular structures that upon activation regulate 
the production and release of the proinflammatory cytokines interleukin IL-1β and 
IL-18 in response to microorganisms or endogenous danger signals [55]. An inflamma - 
some is formed as a result of the interaction of several cytoplasmic proteins, among 
which a NACHT- LRR-PYD-containing protein (NLRP1 or 3) and apoptosis-associated 
speck-like protein (ASC) [56]. Following this, caspase-1 is activated, cleaving the 
precursor of IL-1β into the active form that is secreted from the cell. Cell-mediated 
immune response against C. albicans depends strongly on the production of IL-1β [33, 57]. 
Several polymorphism of the NLRP3 gene have been described in literature. A variable 
number of tandem repeat polymorphism in intron 4 of the CIAS1 gene influences the 
NALP3 production [58]. In 2009, Lev-Sagie and colleagues performed a study 
evaluating the relationship of the CIAS1 length polymorphism, RVVC and VVC in 143 
women with VVS and 182 control patients with no history of vulvodynia. The NLRP3 
gene presents four different tandem sequence repetition alleles; furthermore, those 
alleles could be combined into 10 different genotypes. In both VVS patients and 
control subjects, the homozygosity for the 12 allele repetitions in the intron was the 
most prevalent, whereas the presence of 6 allele repetitions was the least prevalent. 
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The 12,12 genotype was found in a higher percentage of control subjects than in 
patients with and VVS. On the other hand, the 7 repetitions allele was more frequently 
present in patients with VVS than in control subjects, being the genotype 7.7 more 
frequent in RVVC patients than in patients with no history of RVVC and controls 
subjects. Moreover, the Candida induced IL-1β production measured in whole blood 
culture of peripheral blood samples from 27 patients with VVS was higher in the 
samples collected from patients bearing the 12,12 genotype than in those from 
patients who were homozygous for the 7,7 genotype.
The possession of allele 7, which has 200 base pairs less than allele 12, may lead to the 
formation of an altered NLRP3-containing inflammasome, or an inflammasome with 
a reduced biological activity [57]. Homozygous 12,12 genotype is related to a higher 
expression of NLRP3 levels in the cell [58, 59]. It has been proposed that this genotype 
is optimal for the inflammasome function. However, the relationship between VVS 
and NLRP3 length polymorphism has not yet been completely clarified and, potential 
association between NLRP3 length polymorphism and RVVC in women who do not 
have VVS remains to be evaluated.
IL-22 and IDO1 polymorphisms
Another important cytokine released that contributes to host defense against 
mucosal candidiasis is IL-22 [60-62]. It has been reported that a low capacity to 
produce of IL-22 is correlated with chronic and recurrent mucosal candidiasis [63-66]. 
Recent findings using animal models have suggested the importance of tolerance 
in order to reduce the tissue damage caused both by the paghogen and by the 
host immune defense. During infections, this phenomenon is combined with the 
resistance mechanisms decreasing pathogen burden [67, 68] and increasing the 
fitness of host-defense against non virulent C. albicans [69]. In fact, failing to clearing 
the infection, an overwhelming inflammatory reaction including an important vaginal 
PMNs recruitment is associated with RVVC symptoms [70, 71].
An important regulator of mucosal antifungal tolerance is Indoleamine 2,3-dioxygenase 1 
(IDO1) [72], a heme enzyme that catalyzes the first and rate-limiting step in tryptophan 
catabolism to N-formyl-kynurenine (entrez gene Gene ID: 3620 [73], which belongs to 
the kynurenine pathway [74]. Mice experiments have revealed that a IDO1 deficiency 
causes a pathogenic inflammatory response leading a greater susceptibility to 
aspergillosis [75] and mucosal candidiasis [76]. 
De Luca and colleagues have found that genetic variation in the IL-22 and IDO1 genes 
vary significantly between RVVC patients and controls [77]. In addition, since dectin-1 
is known to mediate IL-22 synthesis in the event of mucosal candidiasis  [78], they 
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tested the Y238X SNP in DECTIN1 in their cohort and found that heterozygous 
genotype increased the risk to RVVC (see also above).  Both protective IL-22 and IDO1 
genotypes were associated with higher IL-22 and IDO1 vaginal secretion, respectively. 
In patients carrying the latter genotype, a higher IL-22 production was observed [77]. 
The effect of the genetic polymorphism in the IL-22 gene on the susceptibility to RVVC 
can be explained  due to its effect on IL-22 expression in the vagina. IL-22 controls 
yeast growth by stimulating the secretion of antimicrobial peptides from epithelial 
cells. In addition, through the activation of the STAT3 pathway, IL-22 controls the 
integrity of the epithelium [60].  Subsequently, the mucosal damage is limited and 
the inflammation is kept under control [79]. 
The genetic polymorphism in IDO1 gene described by De Luca and colleagues has a 
protective effect on the event of RVVC, by regulating IDO1 expression. The protective 
variant has a higher IDO1 and therefore kynurenines production. Subsequently, IDO1 
limits tissue damage by inducing tolerance to Candida albicans by inhibting the 
pathological immune reaction that causes the RVVC symptomatology [77].
In conclusion, IL-22 and IDO1 genetic variation affect the susceptibility to RVVC by 
modulating the resistance and tolerance, respectively.
TLR2 Polymorphism and Susceptibility to RVVC
Single nucleotide polymorphisms (SNPs) in both TLRs and C-type lectin-like receptors 
(CLRs) have been described to be associated with an increased susceptibility to both 
systemic [80] and oropharyngeal [81] candidiasis. The TLR2 gene is located on the 
chromosome 4, and TLR2 can also recognize phospholipomannans of C. albicans [20]. 
A SNP in TLR2 is mapped at the position 154625451, introduces a histidine instead of a 
proline at the position 631 of the TLR2 protein. In the present thesis I discussed how 
the mutated amino acid is located between the intracellular domain and the TIR 
domain, and may reduce the rigidity when substituting proline by histidine and how 
this nucleotide position on the TLR2 is conserved in many species. The in silico analysis 
using homology modeling and conservation analysis suggests detrimental effects of 
the mutation on the function of the receptor. Additionally, peripheral blood 
mononuclear cells from healthy volunteers bearing the heterozygous genotype 
secreted very low levels of the T-cell derived cytokines IFN-γ and IL-17, essential 
molecules for mucosal antifungal defense [51, 82]. This finding is in agreement by the 
observations of Ben-Ali et al. who have shown that the 631His TLR2 variant performs 
a reduced NF-κB activation [83]. 
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In the study described in the present thesis, the genotype for the Pro631His poly - 
morphism of the TLR2 gene was associated with a 2.95-fold increase in susceptibility 
to RVVC in the patient cohort. This effect was most likely due to a reduced anti-Candida 
cytokine response, as shown by reduced secretion of the T-cell derived cytokines 
IFN-γ and IL-17. In addition, we have investigated the effect of the Pro631His poly- 
morphism on the MBL levels. Nevertheless, no differences in serum MBL concentrations 
were found between individuals bearing different TLR2 alleles, suggesting that the 
effect of the TLR2 Pro631His polymorphism on the RVVC susceptibility does not rely 
on MBL production.
Conclusions
The data presented above supports the importance of polymorphisms of the genes of 
the innate immune system in the susceptibility to RVVC. MBL, dectin-1 and TLR2 
polymorphisms are related to the recognition of Candida yeasts by the innate immune 
system. As a result, defective recognition of mannans and β-glucans, is taking place 
in patients bearing these polymorphisms, followed by lower host defense reaction. 
Proinflammatory cytokine production has been also shown to be defective in 
individuals bearing these polymorphisms, as is the case with certain haplotypes of 
the NLRP3 gene that have been also associated with susceptibility to RVVC. Moreover, 
IL-22 SNPs that result in a decreased product [77]. In contrast, polymorphisms of the 
IL-4 gene that lead to increased production of the anti-inflammatory IL-4 cytokine can 
result in a diminished NO production, and this may lead to an increased susceptibility 
to RVVC. In contrast, IDO1 regulates kynurenines production and it mediates tolerance 
towards Candida albicans, thus reducing the symptoms in an RVVC context.
In conclusion, these studies suggest an important role of polymorphisms in the genes 
of the innate immune system for susceptibility to RVVC, and it is presumed that the 
relatively few studies performed to date represent only the tip of the iceberg. Future 
studies are warranted to evaluate the entire spectrum of genetic susceptibility to 
RVVC, in order to improve diagnosis and possible future therapy of this important 
clinical syndrome.
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Opportunistic infections in general, and fungal infections in particular, are associated 
with immunosuppressive states. Several well-defined risk factors are known to be 
associated with an increased susceptibility to fungal infections, but not all patients at 
risk develop the disease. This led us to the hypothesis that the genetic make-up of the 
patient is an important component of the risk to acquire an opportunistic fungal 
infection. The aim of this thesis was to assess the role of polymorphisms in genes 
encoding proteins important for antifungal host defense for the susceptibility to 
infections caused by the dimorphic yeast Candida albicans and to opportunistic 
infections in HIV seropositive patients.
The host response against pathogenic microorganisms is initiated through recognition 
by the innate immune system. This recognition is facilitated by Pattern Recognition 
Receptors (PRRs) [1]. PRRs are proteins capable of detecting conserved molecular 
structures on the surface of microorganisms and that subsequently activate signal 
transduction through intracellular mediators in innate immune cells. Ultimately, this 
signal leads to the activation of NF-κB (and other transcription factors), which in turn 
mediates the expression and secretion of pro-inflammatory cytokines. Two of the 
most important proinflammatory cytokines, IL-1β and IL-18, are initially produced as 
inactive precursors and need to be enzymatically cleaved in order to become 
biologically active. This cleavage is performed by the cysteine protease caspase-1, 
which is in turn activated by a multiprotein complex known as the inflammasome 
[2-4]. The process of autophagy, that eliminates dysfunctional organelles and large 
protein complexes by engulfment into double membraned vesicles, influences both 
the antimicrobial activity of the cell and the activation of the inflammasome, crucial 
processes during host defense [5].
In this thesis I presented a series of studies that assessed the role of single nucleotide 
polymorphisms (SNPs) in the genes involved for the innate immune mechanisms 
described above for the susceptibility to Candida infections. The evaluation of the 
genetic susceptibility to opportunistic infections was complemented by functional 
assays with cultures of peripheral blood mononuclear cells, as well as by bioinformatic 
approaches to explain the aberrant function of the mutated protein. 
In Chapter 2 of the thesis we evaluated the role of the Y238X SNP in the CLEC7A gene, 
coding for the archetypical β-glucan receptor dectin-1, as well as the genotype for the 
S12N SNP in its adaptor protein CARD9, in influencing susceptibility to candidemia 
and/or clinical parameters such as severity and dissemination of the infection in a 
cohort of Candida infected patients and non-infected matched controls. Neither of 
these two polymorphisms affected the predisposition to disseminated candidiasis or 
the severity of the disease. The most likely explanation for the lack of association lies 
in the relation of dectin-1 signaling pathway with production of predominantly IL-6 
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and IL-17 upon recognition of Candida albicans. The production of these cytokines 
leads to a strong Th17 response, known to be critical for mucosal (rather than systemic) 
immune response against Candida spp. [6]. Functional studies revealed a lower 
cytokine production in the individuals heterozygous for the Y238X SNP in DECTIN-1. 
However, the remnant cytokine production still produced by cells of these patients 
seems to be sufficient to activate the immune response against Candida in the 
bloodstream. From this and our earlier studies we can thus conclude that defects in 
dectin-1 signaling affects mucosal, but not systemic Candida infections.
In Chapter 3 we investigated the effect of genetic variation related to the inflamma-
tion-modulating gene Caspase-12 for the susceptibility to Candida albicans-related 
sepsis. Caspase-12 has been reported to impair caspase-1 processing of pro-IL-1β and 
pro-IL-18 into the biologically active forms by inhibiting caspase-1 activity. However, 
our results indicate that the Caspase-12 genotype has no significant effect on the 
susceptibility to and severity of systemic infections with Candida (assessed as 
disseminated disease, persistent fungemia, and 30-day mortality), and this lack of 
effect was supported by the fact that Caspase-12 did not influence in-vivo cytokine 
production. In conclusion, despite a previous study that suggested that Caspase-12 
genotype affects the predisposition to bacterial sepsis [7], in our study this conclusion 
was not confirmed in a larger cohort of fungal sepsis patients. Based on these results, 
we suggest that caspase-12 is redundant for host defense against systemic Candida 
albicans infections. 
Autophagy is an important molecular housekeeping process that allows the cell to 
optimize its energy turnover, phagocytosis and antigen presentation. Recent studies 
have also shown that autophagy modulates inflammation, and thus can have an 
additional effects on host defense [8]. In Chapter 4 we evaluated the effect of 
polymorphisms in the autophagy genes ATG16L1 and IRGM [5, 9] on the susceptibility 
to oropharyngeal candidiasis and candidemia, respectively. A lower in vitro TNFα 
production capacity was shown on primary human immune cells bearing the 
ATG16L1*300A allele. Conversely, we obtained a slightly higher IL-8 production under 
similar conditions in cells of individuals bearing the variant allele of the IRGM 
rs13361189 polymorphism. Nevertheless, the genotype of the ATG16L1 and IRGM SNPs 
did not affect the predisposition to either oropharyngeal or systemic candidiasis. In 
previous studies, genetic variation in genes coding for the autophagy regulatory 
proteins have been associated with intracellular bacteria clearance [9]. However, the 
lack of association of the SNPs in ATG16L1 and IRGM with susceptibility to Candida 
infections suggests that the host defense against Candida infections does not rely on 
the autophagy process.
8SUMMARY AND CONCLUSIONS
117
The effect of genetic variability of genes related to PRRs in the susceptibility to 
oropharyngeal candidiasis and other opportunistic infections on HIV patients has 
remained elusive. In Chapter 5 we assessed whether SNPs in CLEC7A and CARD9 genes 
are associated with susceptibility to oropharyngeal candidiasis and other opportunistic 
infections in HIV positive patients. As shown here, genetic variation in CLEC7A (Y238X) 
and CARD9 (S12N) are not associated with the occurrence of opportunistic infections 
in HIV positive patients. The CD4+ count is not significantly different among the 
CLEC7A and CARD9 genotypes, therefore it was not considered as a confounder. In 
contrast, a positive association between the CLEC7A polymorphism and the prevalence 
of pneumonia was found in these patients. This might be due to the fact that patients 
bearing the truncated form of dectin-1 produce lower amounts of IL-6 and IL-17 [6], 
and this is also accompanied by lower IL-22 production. IL-22 is an essential cytokine 
for host defense against pneumonia [13]. In an environment with reduced CD4+ T cell 
numbers and cellular immunity, defects of genes in the innate immune system are 
likely to become more important, as these defects are not masked by a potent 
adaptive immunity. 
Polymorphisms in genes coding for PRRs have been associated with a higher 
susceptibility to infectious diseases, including systemic Candida infections. In Chapter 6, 
we evaluated whether SNPs in genes coding for various PRRs known to be involved 
in Candida recognition or the adaptor molecule CARD9 play a role in the susceptibility 
of otherwise healthy women to recurrent vulvovaginal candidiasis (RVVC). The results 
indicate that DECTIN-1, CARD9, MRC1, TLR1 and TLR4 SNPs had no impact on 
susceptibility of women to RVVC. In the case of the DECTIN-1 Y238X SNP, our results 
suggest that only a complete loss-of-function in the dectin-1 protein is associated 
with a significant risk for infection, as shown previously [6]. In contrast, the P631H 
SNP in TLR2, an important pattern recognition receptor for C. albicans which activates 
innate immune responses both by itself or in synergy with dectin-1 [12], is responsible 
for an almost 3-fold increase in the susceptibility to RVVC. This effect was most likely 
due to a dampened anti-Candida cytokine response, as shown by reduced secretion 
of the T-cell derived cytokines IFN-γ and IL-17. On the other hand, this effect was 
independent of the circulating MBL level, an important component of host defense 
against RVVC.
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Final Conclusions
The goal of the investigations described in the present thesis was to assess the role of 
genetic polymorphisms in genes coding for proteins belonging to the innate immune 
system for the susceptibility to Candida infections: systemic infections, RVVC, and 
OPC (and other opportunistic infections) in HIV patients. What can be concluded 
from these studies? Earlier investigations have reported a role for TLR1 on the one 
hand, and cytokine polymorphisms on the other hand [14], for the susceptibility and 
outcome of candidemia. Less effects have been observed in the present studies of 
polymorphisms in the dectin-1/CARD9 pathway or the inflammasome genes, 
suggesting that redundancy in the pathogen recognition pathways may mask the 
effect of genetic variants in these genes, still allowing for appropriate and sufficient 
recognition and signal transduction in situations in which a certain pathway is less 
effective. 
In contrast to candidemia, a much stronger effect of genetic variation has been 
observed for RVVC. The findings of our studies, coupled with the fact that co-morbidity 
and risk profiles do not explain susceptibility to RVVC in the majority of patients, 
imply that host genetic variants are an important component of the etiology of RVVC. 
The complementary role of genetic, immunologic and bioinformatic approaches was 
evident in the present thesis, since the outcome of each methodology was crucial to 
understand the complete effect of genetic variations in innate immune genes on the 
predisposition to opportunistic infections. 
Although the results reported here are not definitive regarding the genetic burden of 
Candida infections, they provide the proof-of-principle that the genetic background 
of the host is an important risk factor for these infections. However, these studies 
also demonstrate the limits of candidate gene approaches, arguing for the extension 
of the genetic analyses to more comprehensive discovery-based approaches. Future 
studies are thus warranted to extend these results by using whole exome sequencing 
or performing Genome Wide Association Studies (GWAS) in large enough cohorts, in 
order to evaluate genetic variation as a whole, including epistatic interactions. 
Mapping the non-coding regions in genes may show the effect of VNTRs affecting 
gene expression, and it may be related to predisposition to opportunistic infections. 
Analyzing the role of structural variants, as well as epigenetic changes, may 
complement the investigation. Finally, the interaction between genetic variations 
and environment is necessary to bring the predictive model closer to reality. 
In conclusion, variations in genes encoding proteins related to the innate immune 
system have an important effect on the susceptibility to infections. A combination of 
clinical, genetic and bioinformatic approaches is necessary to be able to understand 
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the underlying mechanisms of their effect. This thesis provides the proof-of-principle 
that genetic predisposition is an important component of the etiopathology of 
opportunistic infections, and future genome-wide genetic studies are warranted to 
extend these observations.
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